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Abstract 
Sickle Cell Disease (SCD) is a collection of genetic haemoglobinopathies, the most common 
and severe being homozygous sickle cell anaemia. In the UK, it has been estimated that 1 
in 2000 children are born with SCD.  
The  disease  is  characterised  by  chronic  anaemia,  recurrent  pain  crises  and  vascular 
occlusion.  Neurologically,  there  is  a  high  incidence  of  stroke  in  childhood,  as  well  as 
cognitive dysfunction. Newborn screening programmes and preventative treatments have 
allowed  a  much  longer  lifespan;  however  recently,  neurological  research  has  shifted  to 
characterising subtler aspects of brain development and functioning that may be critically 
important to the individual’s quality of life. 
This thesis overviews the neurological and neurocognitive complications of SCD, and how 
magnetic resonance imaging (MRI) can provide biomarkers for severity of disease. During 
the  PhD,  retrospective  and  prospective  cognitive  and  MRI  data  were  collected  and 
analysed. Diagnostic clinical MRI sequences and advanced MRI sequences were applied, 
as well as a neuropsychological test battery aimed at intelligence and executive function. 
First,  this  thesis  reviews  the  intelligence  literature  in  SCD  and  includes  previously 
unreported data, finding patients, regardless of abnormality seen on conventional MRI, have 
lowered  full-scale  intelligence  quotient  than  controls.  Then,  to  determine  imaging 
biomarkers,  volumetric  differences  and  diffusion  characteristics  were  identified.  Patients 
were found to have decreased volumes of subcortical structures compared to controls, in 
groups corresponding to disease severity. Results from a three-year longitudinal clinical trial 
suggest evidence of atrophy in paediatric patients, with no apparent protective effect of 
treatment.  Diffusion  tensor  imaging  revealed  reduced  white  matter  integrity  across  the 
brain, correlating with recognised markers of disease severity (i.e. oxygen saturation and 
haemoglobin from a full blood count).  
Overall, the four experiments bridge a gap in the cognitive and neuroimaging literature of 
the extent of neurological injury in children with SCD.     5 
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Chapter 1.  Introduction to Sickle Cell Disease 
1.1  Key Triad of Clinical Manifestations 
1.1.1  Irreversibly Sickled Cells  
Haemoglobin is an iron-containing oxygen-transport protein in red blood cells (RBCs) of 
humans. Normal haemoglobin A (HbA) has a globular shape, and is formed from two α and 
two  β  globin  protein  chains  together  with  four  haem  entities.  The  inherited  sickle 
haemoglobin (HbS) gene is a variant of normal HbA, formed from a single amino acid point 
mutation  (glutamic  acid  →  valine)  at  position  6  of  the  β g l o b i n  m o l e c u l e
1.  Normal 
haemoglobin transports oxygen to the body’s tissues; however, HbS has less affinity for 
oxygen than normal haemoglobin
2 and when oxygen is released in RBCs containing HbS, 
the haemoglobin molecules polymerise into dense, elongated sickled cells. 
The process is irreversible, and even when re-exposed to oxygen, the membrane cannot 
return to normal shape
1. The irreversible sickling cells (ISCs), after which the disease is 
named,  is  the  essential  underpinning  of  the  sickle  cell  disease  pathology  –  notably 
haemolytic anaemia, vaso-occlusion and recurrent pain crises (Figure 1-1). 
 
 
 
 
 
 
 
 
 
Figure  1-1.  Blood  sample 
photomicrographs  from  the  first 
description of sickle cell disease in 
1910,  clearly  showing  elongated 
sickle-shaped red blood cells
3.   16 
1.1.2  Vasoocclusion and Vasculopathy 
Vaso-occlusion and chronically impaired blood flow constitute the basis for the most life-
threatening  clinical  aspects  of  SCD,  including  overt  and  silent  strokes,  acute  chest 
syndrome, pulmonary hypertension, kidney damage and the most frequent event, acute 
painful crises.  
There is direct evidence that ISCs are responsible for vaso-occlusion; genotypes that have 
greater  clinical  severity  (i.e.  more  vaso-occlusive  events)  also  have  higher  intracellular 
concentrations  of  HbS,  and  HbS  polymerisation  is  an  integral  risk  for  vaso-occlusion
4.  
However,  it  is  also  clear  that  large  vessels  are  involved  in  the  process
5  and  the 
pathogenesis of vaso-occlusion is most likely multifactorial. Under different circumstances, 
secondary  mechanisms,  such  as  inflammation  and  molecular  factors  affecting  blood 
coagulation and RBC adherence to the endothelium, probably play a role. Figure 1-2 shows 
the mechanisms for a range of possible factors that may contribute to vascular occlusion in 
SCD, as well as potential outcomes due to chronic vaso-occlusion. 
Vasculopathy  is  a  prominent  feature  in  SCD,  involving  several  organs
6,7.  The  most 
commonly affected areas are medium and large vessels of the spleen
8, umbilical vessels
9, 
pulmonary  arterial  tree
10  and  circle  of  Willis
11,  resulting  in  the  following  serious 
complications,  respectively:  autosplenectomy
12,  growth  restriction
13,  pulmonary  disease
14 
and ischaemic stroke
15.   17 
 
Figure  1-2. Physiological processes that lead to vascular occlusion and clinical outcomes. Although the β haemoglobin gene mutation directly affects HbS 
polymerisation,  other  molecular  processes  such  as  platelet  activation  and  inflammatory  responses  can  affect  endothelial  abnormalities  and  contribute  to 
progressive  vasculopathy.  Vaso-occlusion  can  occur  in  other  organs  other  than  the  brain,  and  some  common  clinical  consequences  of  these  events  are 
retinopathy
16, osteonecrosis of the femoral head
17,18, and painful crises
19.    18 
1.1.3  Haemolytic Anaemia 
Haemolytic  anaemia  is  a  life-long  condition  in  those  with  SCD.  Haemolysis  is  the 
breakdown of RBCs; anaemia develops because the destruction of RBCs exceeds the rate 
of  RBC production from bone marrow, and the manner in which the RBC disintegrates 
allows  molecules  containing  iron  into  the  bloodstream.  Other  features  of  haemolytic 
anaemia  include  decreased  haemoglobin  and  haematocrit,  increased  reticulocyte  (i.e. 
young RBC) count and decreased RBC life spans
20–22. 
In those with SCD, anaemia is not present at birth, but develops as foetal haemoglobin 
(HbF) levels decrease and simultaneously HbS synthesis increases. HbS polymerises on 
de-oxygenation and initially may recover to a globular shape on re-oxygenation; but as the 
RBC containing HbS ages, the HbS remains in a polymerised state and the cell becomes 
irreversibly  sickled.  The  RBC  membrane  is  then  more  likely  to  break  down  so  that  the 
contents are released into the circulation and the RBC is broken down by the spleen.  
The relationship between the amount of ISCs in the blood and the haemolytic rate has been 
found  to  be  significant
23,24.  The  percentage  of  ISCs  does  correlate  with  the  degree  of 
haemolysis and the level of anaemia in general; however, the degree of anaemia is not 
consistent  among  individuals  of  the  same  genotype.  Even  within  the  same  individual, 
anaemia severity will vary, suggesting that other mechanisms are involved in mediating the 
production of reticulocytes as well as the degree of haemolysis. Aplastic crises, due to a 
temporary cessation in RBC production (e.g. secondary to infection with parvovirus), and 
acute splenic sequestration crises, due to acute intrasplenic trapping of blood, are the most 
common triggers to exacerbate chronic anaemia with an acute fall in haemoglobin
25. 
1.1.4  Recurrent Painful Episodes 
The acute painful crisis is the third of the cardinal clinical manifestations of SCD, and also 
the most frequent reason for hospital admission
26,27. The only reliable characteristic of sickle 
cell recurrent pain is its variability. The frequency, location, duration, severity and character 
of pain is unpredictable and variable within and among patients
27. The pain spectrum is 
vast; in regard to location, it may be localised, migratory or diffuse
1, could last hours to 
weeks, and anywhere from mild to excruciating in intensity
28. One study reported that a 
typical crisis in an adult is approximately 10.3 days
29. Children and families are taught to 
manage mild pain with rest, hydration and prescribed analgesics, as well as to recognise 
signs of an upcoming crisis that requires hospitalisation. 
It is thought that vaso-occlusive ischaemia, inflammation and infarction are responsible for 
initiation  of  a  painful  crisis
30  on  the  background  of  chronic  haemoglobin  oxygen   19 
desaturation
31. The combination of hypoxia, reperfusion injury and the cycle of ischaemic 
tissue  damage  and  inflammation  makes  sickle  cell  pain  unique
32.  Relative anaemia may 
predict pain in children; however in adults the frequency of painful crises varies directly with 
haemoglobin level and inversely with percentage of HbF
19. In fact, babies as young as 6 
months may experience this pain in the context of HbF decline
1. 
Chronic pain in SCD can result from a number of conditions, including bone infarction, 
avascular necrosis of joints, leg ulcers and chronic osteomyelitis; like other chronic pain 
conditions, sickle cell pain associated with distress and reduced quality of life
33. In children, 
frequent  hospitalisations  result  in  school  absences,  notably  affecting  academic 
achievement
34. Post-traumatic stress has been described in children with history of frequent 
painful crises and their parents
35.  Treatment with hydroxyurea reduces the frequency of 
painful episodes in children
36 as well as adults
37, and cognitive and behavioural therapies, 
as well as early detection of school difficulties, have shown potential in children to improve 
ability to cope with pain
38 and improve quality of life.  
1.1.5  Other Complications 
SCD manifests as a diverse multisystem disorder. Chronic effects of the three hallmarks of 
SCD have a major impact on childhood mortality rate in developed
39 as well as developing 
countries
40, and affects lifelong health. The median age of death is in middle age in the 
developed world, but even now, mortality in childhood is around 7% in the USA
39 although 
it appears to be lower (around 1%) in the UK
41. 
Exacerbations  of  the  chronic  anaemia  can  affect  not  only  the  brain
42,  but  also  may  be 
involved  in  chronic  renal  insufficiency
43  and  in  rare  cases,  liver  function
44.  The  spleen 
functions  poorly  in  SCD;  splenic  enlargement  may  follow  sequestration  and  splenic 
infarction  secondary  to  vaso-occlusion  typically  occurs  in  early  life.  Pulmonary 
abnormalities can also lead to serious illness and death, and include recurrent acute chest 
syndrome,  occurring  in  15-43%  of  patients
45,  sickle  cell  chronic  lung  disease
46  and 
pulmonary hypertension
10,14. Priapism, or persistent, painful swelling of the penis, is also 
common in males
47. Dactylitis, or painful inflammation of a digit occurs in infants
48, and is 
often a prequel to recurrent painful episodes, although whether it predicts severe disease is 
controversial
49.  Microvascular  vaso-occlusion  and  blockage  of  microcirculation  can,  in 
addition  to  causing  pain  directly,  affect  bone  marrow,  leading  to  bone  infarction  and 
predisposition  to  osteomyelitis
50–52.  Often  the  long  bones,  ribs,  sternum,  vertebrae  and 
pelvic bones are affected; a common clinical feature is osteonecrosis of the femoral heads 
of the hips and humeral heads of the shoulders
17,18.   20 
1.2  Epidemiology  
SCD was familiar to people living in Africa long before the first documented patient in 1910
3. 
It  was  called  by  different  ancient  tribal  names
53  and  perhaps  with  different  semantic 
denominations attributed to wide variety of symptoms, rather than a single entity
54. The 
Igbo  of  southeastern  Nigeria  believed  that  children  who  suffered  poor  health  and  died 
typically before 5 years were later reborn to the same family and destined to die again, 
repeating the cycle. These ‘reincarnate children’ were described as having suffered growth 
retardation,  recurrent  febrile  illnesses,  convulsions,  body  aches  and  pains,  protuberant 
abdomen and yellow eyes – most likely caused by sickle cell anaemia
55.   
1949  was  an  important  milestone  in  SCD  research.  In  a  seminal  paper,  Pauling  and 
colleagues
56 were the first to demonstrate chemical differences and the presence of HbS in 
healthy people, carriers and patients, deeming SCA the first molecular disease. Also in that 
year, Neel described the homozygous Mendelian inheritance pattern in the disease
57 after 
much uncertainty of the link between sickle cell trait (one copy of HbS gene) and sickle cell 
anaemia (two copies of HbS gene). Not until 1957 was the mutant HbS gene identified on a 
molecular basis and sequenced
58.  
HbS  is  most  extensively  distributed  in  equatorial  regions  of  the  developing  world.  The 
umbrella  term  of  sickle  cell  disease  includes  the  most  prevalent  genotype  HbSS,  or 
homozygous sickle cell anaemia, but also includes genotypes in which HbS is inherited with 
other  haemoglobin  variants:  haemoglobin  C  (HbSC),  HbS-thalassaemias  (e.g.  HbSβ
0-
thalassaemia and HbSβ
+-thalassaemia) and other much rarer genotypes such as hereditary 
persistence  of  foetal  haemoglobin,  O  Arab,  D  Punjab,  and  S  Antilles.  SCA  and  HbSβ
0-
thalassaemia are the most clinically severe genotypes, while HbSC disease and HbSβ
+-
thalassaemia,  although  relatively  common  in  some  parts  of  the  World  (West  Africa  and 
Greece, respectively), are usually milder in children
59. 
1.2.1  Connection with Malaria 
In the 1950s, reports of populations with high HbS frequencies in Africa observed strikingly 
fewer numbers of people homozygous for HbS (HbSS) than heterozygous for HbS, or those 
that carry one normal haemoglobin A gene and one sickle haemoglobin S gene (HbAS)
60,61. 
Those who were heterozygous for HbS (i.e. with HbAS, commonly called sickle cell trait) 
appeared to have some sort of protection against malaria, and had some selective survival 
advantage
1,62.    21 
The ‘malaria hypothesis’ was recently strengthened
63 by showing a strong geographical link 
on a global scale between frequencies of HbS alleles in the population and high malaria 
endemicity  (Figure  1-3).  Evidence  has  been  established  for  partial  resistance  for 
haemoglobin  variant  carriers,  specifically  sickle  cell  trait,  to  Plasmodium  falciparum 
malaria
64,65. The mechanism of the protective effect of sickle cell trait against malaria has 
been widely debated. However, several epidemiological studies support the hypothesis that 
HbS is protective by restricting disease progression, so that parasitic infections less often 
progress  to  evident  symptoms  because  HbS  cells  limit  ability  of  parasites  to  grow  and 
multiply
66,67, or by early parasitic removal from the circulation
64. 
 
 
 
Figure 1-3. Global distribution of the HbS gene. Piel and colleagues
63 provide evidence for the 
‘malaria hypothesis’ by linking the frequency of HbS allele (top panel) and historical map of 
malaria endemicity
68 and classes of parasite infection rates in children aged 2-10 years (bottom 
panel). 
   22 
1.2.2  Prevalence 
Because of the link to regions of high malaria prevalence, many people carrying the sickle 
gene live in countries on or near the equator or are descendants of those populations but 
living in other regions around the globe. In the Africa, more than 20% have sickle cell trait 
and the prevalence is as high as 45% in areas such as western Uganda, while SCD affects 
approximately 2% of the population
69,70. It has been reported that between 120,000 and 
200,000 babies are born with SCD each year in Africa
70–73.  
SCD is commonly screened for in newborns, affecting 1/1800 births and 1/400 African-
American infants
74, with 1/600 African-American births affected with homozygous SCA
75. 
Similarly, results from the UK National Health Service screening programme covering a two-
year period from 2005-2007 report a national birth prevalence of 1 in 2000, with half of all 
those who carry the gene identified as living in London
76. This secures SCD as the most 
common serious inherited disorder in England
76. 
1.3  Cerebral Ischaemic Events  
1.3.1  Overt Stroke 
Clinical stroke is defined as a focal neurological event lasting more than 24 hours and is 
usually permanent, while transient ischaemic events are focal neurological events lasting 
less than 24 hours (i.e. there is a full clinical recovery)
77. Reversible ischaemic neurological 
deficits last more than 24 hours, but recover fully. None of these clinical definitions require 
neuroimaging confirmation.  
Overt stroke is part of the natural history in children with SCD
78,79. Those with HbSS and 
HbSβ
0-thalassaemia genotypes are at highest risk, although stroke has been documented 
in children with HbSC and HbSβ
+-thalassaemia genotypes
79. Stroke can occur as early as 
6-12 months
80 when HbF decreases and HbS begins to be synthesised; the first decade of 
life, when the onset of strokes typically occur, appears to constitute a ‘critical period’ for 
neurologic  complications  and  subsequent  neurocognitive  morbidity
79,81.  It  has  been 
reported,  without  prophylactic  blood  transfusions  (see  below),  that  between  5-11%  of 
children will experience a clinical stroke during childhood
79,82. 
Strokes can be classified into infarction due to cerebral ischaemia from arterial or venous 
compromise, or haemorrhage. Ischaemic stroke accounts for 70-80% of all cerebrovascular 
episodes, and nearly all episodes in children younger than 15 years and adults older than 
30 years. Intracranial haemorrhage typically occurs between 20 and 30 years of age
79,83,84.   23 
Death from a haemorrhagic event is more common than with ischaemic infarction, as high 
as 50%
15, because of the associated intracranial hypertension and cerebral herniation.  
Overt  stroke  is  usually  associated  with  large  vessel  arterial  disease,  with  evidence  of 
stenosis, or narrowing, of internal carotid arteries and anterior cerebral and middle cerebral 
arteries  of  the  circle  of  Willis
5,85,86.  Other  abnormalities  seen  on  arterial  imaging,  either 
contrast  angiography
5  or  magnetic  resonance  angiography  (MRA)  include  moyamoya 
syndrome
87, and occlusion. Venous sinus thrombosis has also been documented
88.  
The  pathophysiology  of  arterial  vasculopathy  is  multifactorial.  The  body  responds  to 
anaemia by elevating cerebral blood flow velocity that can cause injury to the endothelial 
cells lining the vascular wall
89,90. Increased cerebral blood flow velocity results from adaptive 
vasodilation of vessels to match metabolic demand, causing a reduction in cerebrovascular 
reserve
91.  Further  demand  when  metabolic  rate  is  high  (e.g.  fever)  or  when  there  is  a 
decrease in oxygen delivery (e.g. from worsening anaemia) could cause large and small 
vessel injury/ischaemia
92. Occlusion of small vessels by ISCs can produce microcirculatory 
ischaemia, especially in “borderzones”, where blood flow may be lower
93 in the context of 
large vessel disease and relative hypotension
78.  
Low  haemoglobin,  high  white  blood  cell  count,  previous  transient  ischaemic  attack, 
hypertension, history of acute chest syndrome, high TCD velocities and low haemoglobin 
oxygen  saturation
94–96  are  recognised  risk  factors  for  ischaemic  stroke  in  SCD
79.  Other 
precipitators  for  infarction  include  a  painful  or  acute  chest  crisis,  infection  or  systemic 
illness
84,97  short-term  acute  severe  anaemia
15  and  obstructive  sleep  apnoea  (sleep-
disordered breathing)
98. 
The most common neurological symptom following a cerebrovascular event is the onset of 
hemiparesis
84,90, along with dysphasia and difficulty walking. Visual field deficits and ataxia 
may be detected after posterior circulation territory infarction. In 10-33% of cases, focal 
seizures  also  can  be  seen  with  the  onset  of  symptoms  relating  to  ischaemic 
infarction
97,99,100.  ‘Soft  neurological  signs’
101  may  be  detected  by  careful  neurological 
examination  in  those  with  and  without  a  history  of  previous  clinical  stroke  or  seizures. 
Although  most  patients  typically  make  a  good  recovery  of  motor  function  following 
stroke
84,99,102, many show lasting cognitive deficits in other domains such as intelligence and 
executive functioning
103,104, which will be discussed later. 
1.3.2  Silent Cerebral Infarction 
More common than overt stroke, up to 35% of children will show evidence of silent cerebral 
infarction (SCI)
105, diagnosed using MRI as a lesion is seen in two planes of a scan with no   24 
focal neurological deficit lasting more than 24 hours
78,82,106,107. In children with evidence of 
SCI on MRI, there is a fourteen fold increase in the risk of clinical stroke
108 and further 
lesions seen on MRI
109. Known risk factors for SCI are lower rate for pain crises, history of 
seizures,  increased  leukocyte  count  and  Senegal  beta-globin  haplotype
110,  but  also  low 
baseline haemoglobin
49, male sex and higher baseline systolic blood pressure
111.  
SCI by definition are clinically silent, so timing is unknown; however, it has been postulated 
that brain damage is the result of recurrent micro-infarctions and recurrent acute hypoxic 
damage
42,96,112  secondary  to  severe  anaemia,  diminished  pulmonary  function,  splenic 
sequestration,  aplastic  crisis  and  acute  chest  syndrome
104,113.  Presence  of  SCI  is  also 
associated with poor cognitive outcome
114,115, which will be discussed later. 
1.4  Treatments and Management 
A patient with SCD typically requires a lifetime of treatment and management of symptoms. 
In the UK, there is a national screening programme for infants and established standards of 
medical treatments; however, like any chronic disease, it is very important for families and 
children to get involved in their management of the disease to sustain a high quality of life. 
1.4.1  Screening Programmes 
In developing countries in Africa where health care facilities are insufficient and treatments 
are  limited,  it  has  been  reported  that  of  approximately  50-80%  of  babies  born  will  die 
before 5 years
70. In developed countries, mortality for children with SCD was also high in 
the  20
th  century  before  treatments  became  available
116.  Therefore,  newborn  screening 
programmes are crucial to identify patients early in order to receive the best care possible.  
In the UK, newborn screening diagnostic programmes have been put into place prevent life-
threatening bacterial infection. The spleen, which destroys encapsulated bacterium such as 
Streptococcus pneumoniae, functions poorly and often infarcts in infancy. Pneumococcal 
infection  is  the  most  common  cause  of  death  in  infants;  daily  prophylactic  penicillin  is 
frequently administered, as a randomised trial published in 1986 showed a reduction in 
mortality
117,118. Screening also allows for early monitoring for acute splenic sequestration 
events and dactylitis, as well as identification of other hemoglobinopathies. Folic acid is 
prescribed  in  view  of  the  high  haemolytic  rate.  Many  studies  have  since  shown  that 
neonatal screening, careful follow-up and relatively simple interventions significantly reduce 
morbidity and mortality
81,117,119.    25 
1.4.2  Red Blood Cell Transfusions 
Transfusion is now widely used in the short-term management of acute complications of 
SCD and has a role in the prevention of chronic complications, specifically stroke
120–123. 
Transfusions improve the flow properties of the blood by either lowering the fraction of HbS 
via dilution or “replacing” HbS with HbA. The clinical standard is to maintain an HbS level 
less  than  30%,  reducing  the  incidence  of  recurrent  stroke  from  rates  ranging  from  65-
90%
85,99 to 10%
124,125. Transfusions increase the oxygen-carrying capacity of the blood to 
prevent  cerebrovascular  events
126  by  minimising  viscosity  of  the  blood,  increasing 
haematocrit and improving large vessel stenosis
85. 
Although blood transfusions are standard in clinical practice in developed countries, there 
are also complications. Iron can accumulate in the liver
127 and heart
128, usually monitored 
using  MRI  of  the  liver
129  and  heart
130,  and  treated  with  iron  chelation  therapies.  The 
possibility  that  there  is  an  accumulation  of  iron  in  the  brain  is  still  under  active 
investigation
131.  Hyperviscosity  of  the  blood  can  occur  following  over-transfusion
132. 
Transfusion reactions, possibility-contaminated blood with viruses such as HIV or hepatitis 
C, and alloimmunisation
133, where there is sensitisation of RBC antigens, are also possible 
complications
132. 
1.4.3  Hydroxycarbamide 
Children with SCD who cannot receive regular blood transfusions for any reason may be 
treated with the drug hydroxycarbamide
134 (also known as hydroxyurea). The drug acts to 
inhibit polymerisation of HbS, by increasing percentage of HbF
135 and decreasing cellular 
dehydration
136, both helping to improve red blood cell survival. The risk of stroke is lowered 
by increased  levels of HbF
137,138, and  also by a reduction in white blood cell count and 
expression of cell-adhesion molecules associated with vasoocclusion
139. Controlled trials 
have shown hydroxycarbamide can ameliorate disease severity
140 (i.e. decrease frequency 
of painful crises, acute chest syndrome and the need for blood transfusion
37,134,141), and 
reduce the risk of first stroke
142.  
1.4.4  Bone Marrow Transplantations  
The only cure so far described in SCD is bone marrow transplantation
143, which can be an 
option for children with a matched sibling donor
144. This therapy is considered when there 
are severe complications (e.g. stroke) where there is dependence on blood transfusions. 
Data suggests 92-94% survival overall, with 82-86% event-free rate post-transplantation
145.   26 
Induced  pluripotent  stem  cells
146,  as  well  as  gene  therapy
147,148,  currently  in  pre-clinical 
research can offer promise for the future of SCD treatment
149.   
1.4.5  Psychosocial Interventions 
Another advantage of newborn screening is the involvement of parents very early on as 
care partners with clinicians in managing complications of SCD. Parents and children can 
sometimes  have  considerable  on-going  fear  of  hospital  visits  and  painful  crises;  post-
traumatic stress disorder in children with SCD often mirrors parents’ worries, and has been 
reported to adversely affect recovery
35. Early family education of the aspects of the disease, 
(e.g. learning how to palpate the spleen to feel for enlargement) and identifying lifestyle 
factors (e.g. reduced fluid intake) that increase risk of vaso-occlusive episodes, is critical to 
achieve the best possible comprehensive care. 
Although child survival rate is high in developed countries
41, adolescence is a critical period, 
associated with increased mortality risk
39 as young adults transition from paediatric to adult 
clinics. It is of crucial importance to educate adolescents about the potential severity of 
their disease and how to manage their chronic illness as they start living independently from 
relatives. The transition from paediatric to adult care has been under scrutiny
150, calling for 
‘uninterrupted, coordinated, appropriate care’
151 and for healthcare providers to establish 
multidisciplinary  teams  offering  education,  psychosocial  support  and  vocational 
training
152,153. 
1.5  Stroke Prevention & Clinical Trials 
1.5.1  Primary stroke prevention 
Transcranial Doppler (TCD) ultrasound screening, as well as prophylactic blood transfusion 
in  those  with  high  stroke  risk  from  high  TCD  findings,  has  become  an  established  and 
effective method of primary stroke prevention (i.e. reducing the risk of first stroke). TCD is a 
safe, non-invasive and well-tolerated procedure which measures the blood flow velocity in 
the intracranial vessels
124 (Figure 1-4). Three groups have been identified: those with normal 
TCD velocities (<170cm/sec), those with conditionally abnormal TCD velocities (between 
170cm/sec and 200cm/sec) and those with abnormal velocities (>200cm/sec)
154. In children, 
high  cerebral  blood  flow  velocities  greater  than  200cm/sec  in  the  internal  carotid  and 
middle cerebral arteries are associated with a 40% risk of stroke over the subsequent 3 
years
155, while those with conditionally abnormal velocities have a 7% stroke risk over the 
same period. It has become standard care to prevent stroke by transfusing patients with   27 
velocities  >200cm/sec  and  to  monitor  closely  those  with  conditional  velocities  between 
170-200cm/sec to make sure that they do not cross into the abnormal range.  
 
 
Figure  1-4.  A child with SCD being screened with Transcranial Doppler ultrasound.  Image 
courtesy of Fenella Kirkham; originally published in The Times with parental consent.  
 
1.5.2  Secondary stroke prevention 
As mentioned previously, regular blood transfusions have reportedly reduced the risk of 
recurrent  stroke  from  66-90%  to  10-27%
85,87,99,124,156.  Although  these  treatments  have 
lessened the risk of stroke, approximately 20% of children with a history of stroke who 
receive transfusion therapy will have a second stroke, and approximately 30% will have a 
third  stroke
157.  There  is  currently  no  other  evidence-based  secondary  stroke  prevention 
strategy, but many children are treated with hydroxyurea or aspirin, in addition to or instead 
of blood transfusion, after recurrent stroke, or if blood transfusion is impossible. Those with 
moyamoya  pattern  of  occlusion  with  collateral  vessels  (see  next  chapter)  may  be 
candidates for revascularisation
158.    28 
1.5.3  STOP 
The  Stroke  Prevention  Trial  in  Sickle  Cell  Anemia  (STOP)  randomised  children  with 
abnormal TCD velocities (>200cm/s) to regular transfusion in additional to standard care or 
to standard care alone. There was a 92% reduction in the risk of clinical or overt stroke in 
the transfused arm
123,155. The study was discontinued early because of this clear benefit in 
transfusing children to prevent first stroke
123.  
STOP II followed, recruiting children with abnormal TCD and 30 months or more of regular 
transfusion, who had converted from high-risk to low-risk TCD. The children were randomly 
allocated to continue or discontinue transfusion. Again, the study was halted early because 
too many children reverted to high-risk TCD. From these two clinical trials, the US National 
Heart, Lung, and Blood Institute recommended all children should have TCD screening and 
be transfused if their velocities are greater than 200cm/sec
159 and those children should be 
transfused  indefinitely
156.  Transcranial  Doppler  screening  and  transfusion  for  velocities 
greater than 200cm/sec is now standard National Health Service practice. 
1.5.4  SIT 
The Silent Infarct Transfusion (SIT) trial included only children with evidence of SCI and 
normal TCD measurements, and again used blood transfusion as therapeutic intervention. If 
the child’s TCD was greater than 200cm/sec, blood transfusions were given as standard 
care. The primary hypothesis of the SIT trial was that transfusion therapy would reduce 
occurrence of new clinical stroke and SCI by 86% and that therapy will limit further decline 
of general intellectual ability when compared with observation arm. Additionally, the overall 
benefit of treatment would outweigh the risk associated with the treatment.  
Primary  results  from  the  trial  indicated  that  those  receiving  regular  blood  transfusion 
therapy had have a 58% relative risk reduction in the recurrence of clinical stroke or SCI
160. 
This  was  lower  than  that  predicted  as  well  as  the  reported  risk  reduction  of  blood 
transfusion  therapy  to  prevent  clinical  stroke  in  the  STOP  trial,  but  still  clinically  and 
statistically  significant
123.  Trial  investigators  suggest  blood  transfusion  therapy  possibly 
corrects  for  anaemia,  known  to  be  temporally  associated  with  subclinical  ischaemic 
injury
112,  by  improving  cerebrovascular  reserve
160.  Data  from  this  trial,  which  includes 
children from sites in London, will be discussed in this thesis.  
1.5.5  POMS 
Cohort studies have highlighted the high prevalence of sleep-related breathing disorders 
and nocturnal oxygen desaturation in children with SCD
161 and provided evidence for an   29 
association  with  central  nervous  system  complications,  including  stroke
94  and  cognitive 
dysfunction
162. In the Prevention of Morbidity in Sickle Cell Disease (POMS) study phase 1 
randomised controlled trial, children were randomised for six weeks to either standard care 
or  auto-adjusting  continuous  positive  airways  pressure  (auto-CPAP),  triggered  when 
breathing  was  obstructed.  After  two  weeks,  overnight  haemoglobin  oxygen  saturation 
monitoring was undertaken and if needed, an oxygen concentrator was added to the auto-
CPAP to deliver oxygen to keep oxygen saturation above 94%. The aims of the study were 
to test whether reversing nocturnal oxyhaemoglobin desaturation would prevent cognitive 
morbidity  associated  with  the  disease.  Results  from  the  pilot  study  showed  improved 
processing speed and attention in the treatment group
163. 
Currently,  a  second  POMS  pilot  study  is  in  progress  to  assess  whether  auto-adjusting 
continuous positive pressure therapy or oxygen therapy is more acceptable to patients, 
leading  to  a  larger  proof-of-concept  trial  in  2015,  funded  by  the  National  Institutes  for 
Health Research/Research for Patient Benefit stream. The proposed outcome measures for 
the larger trial are to reduce frequency and severity of pain symptoms, quality of life and 
cognition. The trial will also explore potential reversibility of hypoxic damage to the brain.     
1.6  Conclusion 
This chapter overviewed the main clinical complications of SCD, its prevalence in society, 
treatments and why it is a public health concern. This thesis will focus on the neurological 
aspects, discussed in the following chapters. 
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Chapter 2.  Neuroimaging in Sickle Cell Disease  
Successful  medical  interventions  have  allowed  the  childhood  mortality  rate  of  SCD  to 
decrease and life expectancy to increase. However, cerebrovascular events in childhood 
are relatively common and can significantly limit the full potential of a developing child, 
adolescent or adult.  
MRI is a safe, non-invasive, useful technique for diagnosis and management of SCD-related 
cerebral  infarction,  cerebrovascular  disease  and  other  neurological  abnormalities. 
Conventional structural MRI sequences are routinely used in hospital settings, while more 
advanced  MRI  sequences  are  becoming  more  commonplace  in  research  institutes.  For 
section 2.1, principles of MRI physics are referenced from selected textbooks
164,165. 
2.1  Basics of conventional MRI 
2.1.1  Origin of the MR signal 
In a magnetic field (B0), hydrogen protons found in water content of tissue are aligned in the 
direction of the magnetic field in two possible states: spin-up or spin-down. The strength of 
the magnetic field, as measured in Teslas (T) determines the amount of magnetisation when 
there  is  thermodynamic  equilibrium.  The  sum  of  the  spins  in  B0  amounts  to  the  net 
magnetisation aligned with B0. 
Spinning nuclei precess around B0 at Larmor frequency:  
ω = γ B0 
where  ω i s  t h e  a n g u l a r   frequency  of  the  spins,  γ i s  t h e  g y r o m a g n e t i c  r a t i o  ( a n  i n t r i n s i c  
property  of  hydrogen  protons  set  at  42.56  mHzT-1),  and  B0  is  the  magnitude  of  the 
magnetic  field  strength.  This  equation  implies  that  changes  in  the  magnetic  fields  will 
proportionately affect precession frequencies. Figure 2-1 shows precession frequencies at 
various magnetic strengths. At 1.5T, a common field strength for a clinical MR scanner, 
protons precess around the main magnetic field at 64MHz.   31 
 
Figure 2-1. Proton precession. Protons precess around the axis of the main magnetic field (B0) 
at the Larmor frequency, which at 1.5T scanner is 64MHz. 
 
A coil is used to produce an oscillating magnetic field, called a radiofrequency (RF) pulse, 
which precisely matches the natural precession frequency. This causes a torque that is 
orthogonal to the main magnetic field, which tips the magnetisation out of equilibrium into 
the transverse plane. Over time, the transverse magnetisation decays away exponentially as 
the  spins  dephase  with  respect  to  each  other  and  return  to  equilibrium,  restoring  the 
magnetisation along the direction of the main magnetic field B0. 
To achieve maximum signal, it is best to apply an oscillating magnetic field that tips the 
magnetisation into the transverse plane. The desired flip angle (α) depends on the amount 
of time the RF pulse is applied. The RF pulse oscillates at the Larmor frequency, and it 
creates a magnetic field that is perpendicular and orthogonal to B0. This new magnetic field 
(B1) is static when perceived in a rotating frame of reference. The equation that describes 
RF pulses is: 
flip angle (α) = γ B1 tp 
where B1 is the strength of the RF magnetic field and tp is the duration of the pulse. With 
this equation, one can change the strength of the pulse to create different flip angles. When 
the excess energy is re-emitted, that is when the MR signal can be collected. 
When  an  RF  pulse  that  matches  the  precession  frequency  of  the  spins  is  applied,  this 
affects spin equilibrium because of an exchange of energy. Absorption of electromagnetic 
energy will only happen when protons spin at the same frequency as the RF pulse. The 
term relaxation is used to describe when the system returns to thermal equilibrium, or their   32 
original energy state, and there is an emission of electromagnetic energy back into the 
environment – this is the signal that is measured in MRI. 
2.1.2  Relaxation Times 
Relaxation times are fundamental parameters that reflect the tissue ‘environment’, both due 
to the nature of the spins themselves or due to the magnetic field. There are two main 
features of relaxation: realignment of the spins along the transverse plane as they lose the 
energy they absorbed from the RF pulse, and dephasing of spins following the RF pulse. 
T1 relaxation, also known as ‘spin-lattice relaxation’ or longitudinal relaxation, refers to an 
exponential  growth  of  longitudinal  magnetisation,  where  the  spins  return  to  a  thermal 
equilibrium state in the main magnetic field B0. It is called longitudinal relaxation because 
the spins return to the longitudinal plane.  
T2 relaxation, also called ‘spin-spin relaxation’ or transverse relaxation, is a process that 
causes spins to get out of phase with each other. It causes a loss of magnetisation in the 
transverse plane. T2 is governed by an exponential decay, and can be described as a time 
constant  of  the  transverse  magnetisation  after  an  RF  pulse  in  a  homogeneous  static 
magnetic  field.  The  contrast  obtained  in  a  spin-echo  sequence,  where  the  effects  of 
magnetic field inhomogeneity are reversed are, in part, dependent on T2. 
T2* is also a time constant for the transverse magnetisation decay, but where the effects of 
an inhomogeneous field are not compensated, as is the case for a gradient-echo sequence. 
It  is  described  as  the  combined  effect  of  T2  decay  plus  the  decay  due  to  local 
inhomogeneities in the main magnetic field B0.  
T2* and T2 dephasing happens within a few hundred milliseconds (T2* is shorter than T2). 
T1 is slower, taking several seconds before the net magnetization is restored along the 
transverse plane. 
2.1.3  Contrast 
Other important parameters that describe pulse sequences are echo time (TE), the time 
between the first excitation RF pulse and when the ‘echo’ signal is formed, and repetition 
time  (TR),  the  time  between  subsequent  excitation  RF  pulses.  These  two  parameters 
determine the contrast in image, and different combinations will produce different degrees 
of contrast between tissues. Proton density (PD) is a characteristic of tissue describing the 
number of spins absorbing and emitting energy. Each tissue has a specific PD, T1 and T2 
time, and the signal depends on these three factors (Figure 2-2).   33 
Changing TR will affect the contrast between tissues with different T1 relaxation times and 
changing  TE  will  affect  contrast  between  tissues  with  different  T2  relaxation  times.  For 
example, a tissue with a long TE and TR, such as CSF, will be dark in a T1-weighted image 
(that has a short TE and short TR), but bright in a T2-weighted image (that has a long TE 
and long TR).  
 
 
Figure 2-2. Relaxation times of various tissues at 1.5T
166. Right panel: Contrast in PD-, T1- 
and T2/T2*-weighted images depends on combinations of TE and TR. 
 
2.1.4  Spin echo and Gradient echo sequences 
Both spin echo (SE) and gradient echo (GE) sequences start with an initial 90
o RF excitation 
pulse which produces magnetisation in the transverse plane. In a SE sequence, after the 
initial RF pulse and the magnetisation decays away, a 180
o RF pulse is then applied. This 
pulse flips the magnetisation vectors, so they precess in the same direction and at the 
same speed as before (i.e. the protons that are moving faster move towards the back and 
those that are moving slower move towards the front so they all end up in phase). In this 
way the transverse magnetisation is refocused to form an echo. 
GE imaging utilises a negative field gradient applied just after the initial 90
o RF pulse, which 
causes  deliberate  rapid  dephasing  of  the  spins.  A  positive  gradient  is  then  applied  to 
reverse the previous magnetic field gradient that rephases the spins (i.e. spins that were 
precessing at a low frequency due to position along the gradient direction will now precess 
at a higher frequency and vice versa). 
One way to represent a pulse sequence is through a diagram that gives the relative timing 
as well as the amplitude of each pulse (Figure 2-3).   34 
 
Figure  2-3. Pulse sequence diagrams for spin echo and gradient echo sequences. A (red): 
Spin echo sequence uses an initial 90
o pulse, then an 180
o refocusing pulse to rephase the 
spins. B (blue): Gradient echo sequence uses an initial pulse (flip angles can vary), followed by 
negative and positive gradients to rephase the spins. 
 
T1-weighted GE images are often used anatomically, because contrast between different 
tissue types is high: water-based tissues (i.e. grey matter) appear mid-grey and fat-based 
tissues (i.e. white matter) are brighter. T2-weighted SE images are generally used for clinical 
diagnosis  of  pathology,  because  tissues  with  the  longest  T2-relaxation  times  (i.e. 
cerebrospinal fluid, oedema and lesions) appear bright (Figure 2-4).   35 
 
Figure 2-4. T1- and T2-weighted images of a healthy 24-year-old female. Left panel shows a 
T1-weighted  (Fast  Low-Angle  Shot;  FLASH)  spoiled  gradient  echo  sequence.  Right  panel 
shows a T2-weighted (turbo spin echo sequence).  
 
2.2  Diffusion MRI 
Diffusion MRI utilises the concept of water displacement in brain tissues that allows for in 
vivo analysis of white matter microstructural integrity.  
In water, molecules move with a kinetic energy in a random fashion, called Brownian motion 
or random translational motion. The mean squared displacement of water molecules <r
2> is 
proportional to the diffusion coefficient (D) and time (t) over which the diffusion process is 
observed, and can be accurately described by Einstein’s equation: 
<r
2> = 6Dt 
D is dependent on temperature, but at normal body temperature (37
oC), diffusivity of water 
is approximately 3.0 x 10
-3 mm
2/s. The displacement of water molecules is also governed 
by Fick’s law: Jx = -D(dC/dX), which states that the diffusive flux of concentration will go 
from regions of high concentrations to low concentrations. In the case of water, from which 
the MR signal is concerned, the diffusive process is referred to as self-diffusion.   36 
2.2.1  Diffusion-Weighted Imaging 
In the human brain, there is not only water, but also microscopic structures such as axons, 
myelin  and  glial  cells  that  affect  the  mobility  of  water  molecules.  The  displacement  is 
different in various tissues. In diffusion imaging, the ‘apparent’ diffusion coefficient (ADC)
167 
is measured within each volume pixel element (voxel), which represents an index of the 
mobility of water molecules inside biological tissues. 
Where  there  is  little  hindrance  to  diffusion,  water  has  an  isotropic  diffusion  profile  in 
accordance  to  Einstein  and  Fick’s  principles.  In  isotropic  diffusion,  the  net  direction  of 
diffusion is 0 since it is uniform in all directions. Diffusion is isotropic in cerebrospinal fluid, 
where there is also high diffusivity, and in grey matter where there is low diffusivity. White 
matter however, displays an anisotropic diffusion profile. Water molecules are constrained 
in white matter, where the presence of cell membranes, myelin, axons and other ‘biological 
barriers’
167,168 hinder diffusion so that diffusion is greatest along specific directions (Figure 2-
5). 
 
 
Figure  2-5.  Diffusion  characteristics  in  nervous  tissue.  Diffusion  is  influenced  by  cellular 
microstructures, which can restrict the mobility of water molecules. In isotropic diffusion, such 
as an area of grey matter (A), molecules (blue) can displace in all directions, while in anisotropic 
diffusion, such as white matter fibre tracts (B), axonal membranes and myelin sheaths present 
barriers, therefore restricting the diffusion of water molecules in a preferential direction
169.   37 
Pulse sequences are made sensitive to diffusion by adding diffusion gradients in certain 
directions on either side of the 180
o pulse in a T2-weighted spin-echo sequence. The b-
value  is  the  parameter  that  measures  diffusion  sensitivity  by  altering  the  strength  and 
direction of the gradient. A b-value has units of seconds per square millimetre; a b-value of 
0 will result in a typical T2-weighted image, while a typical diffusion-weighted b-value is 
1000 s/mm
2. Random motion of the water molecules in the direction of the gradient will 
result in signal loss on the image because of phase changes of the spins moving in the 
gradient direction, which results in rapid dephasing and loss of signal. Contrast in DWI is 
dependent on T2, the ADC and the b-value, and differences in the ADC signal are based on 
differential diffusion of tissues within the parenchyma.  
ADC  is  generally  measured  along  three  axes,  and  the  mean  ADC  is  used  for  clinical 
purposes such as acute stroke, where diffusion abnormality due to ischaemia appears a 
few hours after onset
170. Clinically, ADC in acute stroke is thought to reflect shifts in fluid 
between intracellular and extracellular spaces
171. 
2.2.2  Diffusion Tensor Imaging 
Diffusion  tenor  imaging  (DTI)  was  developed  to  characterise  diffusion  anisotropy,  which 
cannot be determined with the measure of diffusion in three directions. Anisotropy can be 
quantified by measuring the diffusion tensor, which requires measurements in at least six 
directions
172. In the case of anisotropic diffusion, the tensor can be visualised as an ellipsoid 
(Figure  2-6),  with  three  orthogonal  directions  (eigenvectors;  λ1,  λ2,  λ3)  and  diffusion 
coefficient values for each direction (eigenvalues: v1, v2, v3). The tensor reverts to a sphere 
when diffusion is isotropic. 
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Figure 2-6. Isotropic and anisotropic diffusion tensors, adapted from Wiegell et al.
173). Isotropic 
diffusion  (right)  is  characterised  by  three  eigenvalues  approximately  equal  (λ1  ~  λ2  ~  λ3) 
whereas anisotropic diffusion (left) is characterised by the magnitude of the principle diffusion 
orientation larger than the two perpendicular directions (λ1 ≥ λ2 ≥ λ3). 
 
From  the  diffusion  tensor  model,  several  quantitative  metrics  can  be  calculated.  The 
average water molecular displacement (i.e. mean diffusivity; MD) can be measured as the 
mean  of  the  three  eigenvalues.  This  is  equivalent  to  the  ADC  determined  from  three 
directions. The degree of anisotropy, or fractional anisotropy (FA), can be derived from the 
standard deviations of the three eigenvalues. 
FA and MD both indicate differences in underlying tissue microstructure. FA values range 
from  0  (complete  isotropy)  to  1  (complete  anisotropy).  High  FA  values  result  when  the 
principal  eigenvalue  (λ1)  is  greater  than  the  other  two  (λ2,  λ3),  reflecting  coherence, 
organisation and/or density of the local tract. MD, which measures the overall magnitude of 
water diffusion, increases when there is a loss of structure, such as axonal damage or 
demyelination  (i.e.  degeneration  of  microstructural  cell  barriers)
174.  Other  metrics  of 
diffusivity,  such  as  axial  diffusivity  (AD),  the  magnitude  of  diffusion  along  the  principal 
eigenvector of the diffusion tensor (λ1), and radial diffusivity (RD), the average magnitude of 
diffusion along the two perpendicular eigenvectors (λ2, λ3), provide additional information 
about  the  nature  of  water  diffusion  changes  that  have  been  related  to  myelination  and 
axonal damage
175. 
There are two common ways of analysing DTI data: using a voxel-based approach across 
the  whole  brain,  or  a  region-of-interest  approach  using  DTI  tractography.  Tractography 
relies  on  colour-coded  maps
176,  given  by  the  principle  eigenvector,  to  visualise  the 
orientation  of  the  tensor  within  each  voxel  and  to  reconstruct  the  major  white  matter   39 
pathways of the brain by following the continuity and direction of maximum diffusion along 
white matter fibres from voxel to voxel
177 (Figure 2-7). This non-invasive MRI technique is 
able to virtually dissect white matter pathways of the living human brain
178, and the method 
can be applied in neurological and psychiatric disorders, as well as healthy development 
and aging
174. 
 
 
Figure 2-7. DIffusion tensor imaging and tractography. Top panel shows a FA map, and the 
enlarged area shows the colour-coded principle eigenvectors (i.e.  red= left/right orientation, 
green= anterior/posterior orientation, blue= inferior/superior orientation). An algorithm can be 
used to trace paths following the orientations at each voxel, called streamlines, and virtually 
‘dissect’ white matter pathways. Bottom panel is a tractography image showing the corpus 
callosum (red), internal capsule/corona radiata (yellow) and inferior fronto-occipital fasciculus 
(blue). This image won first prize at the 2011-2012 UCL Graduate School’s ‘Research Images 
as Art/Art Images as Research’ competition.   40 
2.3  Neuroimaging Findings 
MRI studies have showed that the majority of overt stroke and SCI occur from a distribution 
from the internal carotid artery
109, and pathologies are frequently seen in tissue within the 
anterior  cerebral  and  middle  cerebral  arterial  distribution
179,180.  MRA  studies  confirm  this 
pattern, as publications have reported stenosis (narrowing) or occlusion of these vessels 
with relative sparing of the posterior circulation, other than tortuosity
1,181 (Figure 2-8). Stroke 
and SCI from vertebrobasilar artery circulation occlusion are less common, but have been 
reported
180,181.  Cerebral infarction is rarely fatal, however approximately 11% of patients 
with genotype HbSS will experience a clinically apparent stroke by age 20, and up to 24% 
by age 45
79. SCI can develop very early in life, with rates between 11-15% in children less 
than 2 years
107,182,183. By 6 years of age, at least 25% of children with show evidence of 
SCI
183, and up to 37% by 14 years of age
184. 
 
 
Figure 2-8. Example of a 19-year-old female with HbSS who experienced a clinical stroke. Left 
panel shows occlusion of the right middle cerebral artery on MRA, and the right panel shows 
corresponding hyperintense signal on T2-weighted MRI, indicating area of infarction. 
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2.3.1  Radiological Findings 
Although  stroke  is  identified  by  abrupt  onset  of  neurological  deficit,  the  term  ‘covert 
stroke’
185,  or  SCI  was  first  described  in  the  Cooperative  Study  in  Sickle  Cell  Disease 
(CSSCD)
82  to  radiologically  define  an  abnormal  MRI  result  in  the  absence  of  overt 
neurological symptoms. An accepted definition of SCI, described for the SIT trial
111,186, is “a 
MRI lesion measuring at least 3mm in greatest linear dimension, visible in two planes of T2-
weighted images (axial and coronal)”. SCI can be concurrent with neurological symptoms 
lasting  under  24  hours,  but  must  occur  in  the  absence  of  a  focal  neurological  deficit 
compatible with the anatomic location of the MRI lesion
187.  
Many studies describe a localisation of SCI to deep white matter, particularly in the arterial 
borderzones
104,180,181,183,188,  where  flow  is  more  vulnerable  (Figure  2-9).  Moser  and 
colleagues
82 found that localised infarcts are usually confined to borderzone white matter 
while  extensive  lesions  involve  both  cortex  and  deep  white  matter.  Infarcts  in  the 
subcortical grey matter structures (i.e. head of caudate, cerebellum) are less common
180,181. 
Brain injury in children with SCD also extends to concurrent vasculopathy
189 and moyamoya 
syndrome seen on MRA
82,190,191, as well as generalised
82,104 and focal cortical atrophy
192–195. 
  
 
Figure 2-9. An example of right frontal silent cerebral infarcts in a 14-year-old male with HbSS. 
Both T2-weighted image (left) and fluid-attenuated inversion recovery (FLAIR, right) image show 
hyperintense signal corresponding to the lesion site.    42 
2.3.2  Acute Silent Cerebral Ischaemic Events 
It has been argued that categorically dividing ischaemic events between clinical stroke and 
SCI may be an oversimplification of the spectrum of brain injury in SCD
196. Recent research 
has shown that acute silent cerebral ischaemic events (ASCIE)
112,196, following  acute severe 
anaemia
42,110,197,198, can be detectable using DWI. In acute ischaemia, an area of oedema in 
the  brain  has  a  rapid  decline  in  proton  density  and  appears  hyperintense  on  DWI  and 
decreased on an ADC map, persisting for 10-14 days post-event
170, which can differentiate 
acute stroke from more remote events
42. These lesions, which may be transient, are likely 
under the detection of T2-weighted MRI until SCI develop.   
These findings are line with the hypothesis put forward by Steen and colleagues
106: the SCD 
brain is a model of diffuse brain injury, microstructural changes in cerebral tissue results 
from chronic recurrent ischaemic insult, and these changes may not pass the sensitivity 
threshold that can be visualised on MRI at current clinical field strengths in widespread use. 
2.3.3  Quantitative Neuroimaging Findings  
In the two decades since MRI was first used to describe the spectrum of neuroimaging 
abnormalities in SCD, technology has been improving: clinical MRI hardware and software 
are more advanced, and sophisticated sequences for quantitative processing techniques 
are being applied to SCD to describe subtle abnormality.  
A voxel-based morphometry study
199 using T1-weighted imaging found that in a group with 
a  history  of  SCI,  there  were  significant  decreases  in  white  matter  density  extending 
bilaterally from anterior frontal lobe along the ventricles to parieto-occipital lobes, as well as 
along the corpus callosum (Figure 2-10). This study is consistent with the pattern of white 
matter lesions described earlier, but also suggests that patients without visible infarcts on 
T2-weighted MRI may have compromised white matter. 
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Figure 2-10. Decreased white matter density in the arterial borderzone distribution: results from 
a voxel-based morphometry study
199. (A) Areas of significantly decreased white matter density 
in the SCD patients with evidence of SCI compared to controls. (B) In patients with no evidence 
of SCI, there were similar bilateral white matter density decreases compared to controls, but 
the spatial extent of white matter changes were less compared to the group with lesions.  
 
Grey matter volume has also been investigated. One report showed significant reduction in 
total subcortical grey matter volume (i.e. basal ganglia volume) as compared to cortical grey 
matter volume
200. In children without evidence of SCI, decreased grey matter volume in 
bilateral frontal, temporal and parietal lobes was found to correlate with low IQ
201, and one 
study  reported  significant  thinning  of  cortex  in  older  children  as  compared  to  younger 
patients in the posterior medial surfaces of both hemispheres
202. 
A  DWI  study  showed  significant  increases  in  mean  regional  ADC  of  patients  relative  to 
controls in six regions (left and right frontal, left and right cerebellum, pons, vermis), and in 
patients with no evidence of infarct, there was increased ADC in four regions (excluding 
pons and vermis)
203. Helton and colleagues
204 combined perfusion and diffusion data and 
found that abnormal appearing white matter, due to leukoencephalopathy and SCI, had not 
only  decreased  cerebral  blood  flow  using  arterial  spin  labelling  perfusion  MRI  but  also 
showed decreased FA by DTI.  
There are two recent DTI studies of note. One study looked at two groups of children with 
SCA, some of whom had mild gliosis although none had SCI. Increases in diffusivity and 
reduced FA in the body of the corpus callosum were found only in patients with mild gliosis, 
while reduced FA in the centrum semiovale was found in the no-SCI group
205. Another study 
compared  sixteen  SCA  patients  in  a  combined  quantitative  DTI  and  deterministic 
tractography analysis. This study used various regions-of-interest across the brain, finding 
reduced  FA  in  the  corpus  callosum,  centrum  semiovale,  periventricular  areas  and 
subcortical white matter ROIs. Deterministic tractography of the corpus callosum was also   44 
used, showing reduced fibre count (i.e. streamlines) and reduced FA in the anterior body of 
the corpus callosum
206. 
2.4  Neurocognitive Findings 
Brown  and  colleagues
113  suggest  some  factors  that  accumulate  over  time,  and  could 
explain the compromised intellectual functioning in children with SCD. Recurrent micro-
infarctions of the central nervous system, possibly undetected by screening measures, may 
affect  general  functioning
207.  Additionally,  conditions  secondary  to  anaemia,  such  as 
diminished pulmonary function and chronic hypoxic damage can cause brain damage
208. 
While the exact mechanisms underpinning cognitive dysfunction in SCD are unknown, there 
is a substantial literature characterising the effect of SCD on cognition. 
2.4.1  General Intelligence 
Intelligence quotient (IQ) is the most commonly reported and widely studied standardised 
measure of cognitive ability in SCD. The first published study was in 1963 in the USA, 
finding  no  differences  between  children  with  SCD  and  a  group  of  siblings
209.  Further 
attention to the subject was most likely deferred due to the on-going civil rights movement 
of  the  1960s,  where  prejudiced  beliefs  that  black  people  were  inferior  to  whites  were 
common. 
Early studies in the 1980s and 1990s included patient groups without information from MRI, 
but generally excluded those with history of stroke or abnormal neurological exam. Results 
from studies at that time were mixed; some reported no differences in full-scale IQ (FSIQ) 
between patients and controls
210–212, others found patients had lowered intelligence scores 
than matched controls
102,213–215.  
With the routine use of MRI added in the mid-1990s, patients were classed into groups 
based on history of stroke and presence or absence of SCI. Reports from the CSSCD
104,216 
were  the  first  to  show  a  general  trend  of  a  spectrum  of  decreasing  intelligence 
corresponding to lesion burden. Since then, several studies have confirmed that children 
with history of overt stroke perform significantly worse than children with no stroke
104,217–222. 
Further, evidence has also suggested children with silent cerebral infarcts perform worse 
than those with normal MRI
199,203,216,218,220,223, and that large lesion size is associated with 
lower FSIQ
224,225. More studies are needed to elucidate the differences between children 
with SCD and normal MRI compared to controls; this topic will be discussed in Chapter 4.   45 
2.4.2  Executive Functioning 
Historically, SCD has been associated with deficits in executive functioning, an umbrella 
term  for  frontal  lobe  functions  such  as  inhibition,  planning,  organisation,  processing, 
decision-making,  mental  flexibility  and  working  memory.  Berkelhammer  and  colleagues 
constructed a systematic review of the neurocognitive literature in 2007
115, and found 11 
out of 13 studies found executive function and attention were impaired in children with 
SCD, and a strong relationship between degree of cerebral damage and location of injury 
with executive function performance. 
It has been reported that children with SCD show deficits in sustained attention
219,226,227 and 
cognitive flexibility
217,228 as well as working memory
188,217,221,226,229–231. Studies have related 
some  executive  function  deficits  to  presence  of  frontal  lobe  lesions
226,227,232,  and  a 
publication that used cognitive screening found the Test of Variables of Attention task was 
sensitive  and  specific  to  identify  86%  of  children  with  SCI
233.  There  are  fewer  studies 
comparing  those  with  no  evidence  of  SCI  and  sibling  controls;  the  results  are  mixed. 
Patients with normal MRI were found to have deficits in visuomotor functions compared to 
siblings
226,227,  while  other  studies  found  no  differences  between  those  two  groups  in 
sustained visual attention
203, working memory
221 or set-shifting
217. A study of neurologically 
intact adults with SCD showed deficits in processing speed, working memory and other 
executive functions compared to controls
234. 
2.4.3  Neurocognitive biomarkers 
Some indices of disease severity play a role as biomarkers of cognitive functioning. The 
most  commonly  reported  marker  is  anaemia,  usually  measured  by  haematocrit  or 
haemoglobin levels. Low daytime oxygen saturation may reflect state of chronic hypoxia, 
and haemoglobin levels are likely to act as a surrogate marker for reduced oxygen delivery 
to the brain
234. In neurologically intact children (i.e. without cerebrovascular abnormalities), 
anaemia severity has shown moderate to large correlations with intelligence
113,194,218,235, and 
may even be related to verbal short-term memory
231 and severity of cognitive impairments 
in children with SCI
194,218. Anaemia may also interact with social/environmental factors such 
as  socioeconomic  status
236.  Low  nocturnal  peripheral  oxygen  saturation  was  associated 
with reduced performance on the Tower of London test, which measures strategic planning 
and rule-learning
162.  
Associations  have  been  found  between  elevated  TCD  velocities  and  performance  on 
sustained  attention
237  and  executive  functioning
228,238,  as  measured  by  the  Behavioural 
Rating Inventory of Executive Function by a parent.    46 
2.5  Conclusion 
This  chapter  has  overviewed  neurological  and  neurocognitive  complications  associated 
with SCD. Research has shown ischaemic events significantly impact brain development 
and function. However in children with no imaging evidence of ischaemic stroke or SCI, it is 
still unclear what chronic disease-specific effects, such as anaemia and hypoxia, have on 
the  brain.  The  scope  of  this  thesis  is  to  use  quantitative  MRI  analysis  and 
neuropsychological testing to investigate any neurological differences between patients and 
their siblings that may underpin the effect of chronic illness. 
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Chapter 3.  Methods 
This thesis includes three different cohorts of children and adults with SCD. Participants 
recruited  during  the  studentship  (2012-2013  London  Cohort)  will  be  described  in  this 
section, while participants from retrospective studies at UCL Institute of Child Health and 
participants included from the multicentre SIT trial will be described in their corresponding 
chapters.  
Details  of  participant  recruitment,  MRI  protocol  and  radiology  assessment,  cognitive 
assessment and additional information will be discussed here.  
3.1  2012-2013 London Cohort Participant Recruitment 
The 2012-2013 London Cohort of SCD patients and their sibling controls were recruited 
from different ethical approval applications and different NHS sites across London. Figure 
3-1 outlines the participant recruitment. 
Inclusion criteria for recruitment were children older than 8 years and adults with sickle cell 
disease (encompassing genotypes HbSS and HbSC). All participants were screened for any 
contraindications for MRI by prior telephone conversation with parents. Informed consent 
was given for all participants prior to MRI and cognitive assessment. 
3.1.1  MSc Project: Executive Function – Impact of Pain 
The first participants in this cohort were previously recruited in 2011 as part of an MSc 
project  investigating  the  effect  of  pain  on  executive  functioning  in  children  with  SCD. 
Included in the ethics were neuropsychological assessment of intelligence and executive 
functions, questionnaires regarding the child’s current pain and MRI investigation. Ethical 
approval was granted by Southampton Research Ethics Committee (11/H0502/5) and fully 
informed consent was taken from all patients and their parent/guardian. 
Demographics  are  reported  in  Table  3-1.  Participants  were  recruited  from  four  London 
sites:  
•  North Middlesex University Hospital NHS Trust (10 patients, 4 controls),  
•  Whittington Hospital NHS Trust (16 patients, 4 controls),  
•  Guy’s and St Thomas’ NHS Foundation Trust (1 patient, 2 controls), and  
•  St Mary’s Hospital Imperial College NHS Trust (1 patient, 2 controls).    48 
2011 MSc Project  n  Age  Gender  Genotype 
Patients  28  9-16 years  17M, 11F  28 HbSS 
Controls  12  9-18 years  7M, 5F 
6 HbAS, 5 HbAA 
1 unknown 
Table 3-1. Details of demographics for the participants recruited from the 2011 MSc Project.  
 
3.1.2  Longitudinal Project 
In  2012,  ethical  approval  was  granted  by  Portsmouth  Research  Ethics  Committee 
(13/SC/0042) to recruit and scan patients and sibling controls from three cohorts of children 
and adults with SCD (2000-2001 Baby cohort
239,240, Non-randomised SIT trial patients
160,186, 
and 2000-2002 East London cohort
199,241, originally recruited from 1991-1994) as part of a 
longitudinal follow-up investigation. Each cohort varied in age and details of original study 
protocol.   
!  2000-2001 Baby Cohort 
An original infant cohort of 14 patients and 14 controls from the Royal London Hospital, 
East London between 2000 and 2001 were selected for follow-up. Studies investigating 
neurodevelopmental delay and precursors of executive function from this cohort have been 
published
239,240. 
From  the  original  patient  cohort,  10  patients  were  recruited  to  the  2012-2013  London 
Cohort (1 parent refused participation, 3 patients moved away from London). Two of the 14 
original  controls  were  recruited,  together  with  2  contemporaneous  sibling  controls. 
Demographics are reported in Table 3-2. 
 
2000-2001 
Baby Cohort 
(Royal London) 
n  Age  Gender  Genotype 
Patients  10  12-13 years  7M, 3F  10 HbSS 
Controls  4  8-19 years  1M, 3F  2 HbAS, 2 HbAA 
Table  3-2.  Details  of  demographics  for  the  participants  of  the  London  2012-2013  cohort, 
originally from the 2000-2002 Baby Cohort, recruited from the Royal London hospital.  
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!  Non-randomised SIT Trial Patients 
Patients screened, but not randomised, from London centres of the SIT trial were recruited. 
SIT  trial  screening  MRI  investigation  was  performed  at  Great  Ormond  Street  Hospital 
between  2005  and  2010.  Reasons  for  non-randomisation  to  the  trial  were  absence  of 
baseline SCI or refused participation.  
Only patients from Royal London hospital were recruited, as part of the R&D approval. Nine 
patients were recruited out of a possible 20: 1 patient refused participation, 1 patient died, 
6 patients could not be contacted, and 3 patients were already recruited from the 2000-
2001  Baby  Cohort.  One  sibling  patient  and  4  contemporaneous  sibling  controls  were 
recruited from the Royal London Hospital. Demographics are reported in Table 3-3.  
 
Non-randomised 
SIT Cohort  
(Royal London) 
n  Age  Gender  Genotype 
Patients  10  10-18 years  3M, 7F  9 HbSS, 1 HbSC 
Controls  4  8-18 years  2M, 2F  4 HbAA 
Table  3-3.  Details  of  demographics  for  the  participants  of  the  London  2012-2013  cohort, 
originally not randomised to the SIT trial, recruited from the Royal London hospital. 
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!  2000-2002 East London Cohort 
Patients  from  the  original  East  London  cohort  were  first  scanned  in  the  1990s
217,  and 
returned again between 2000-2002 for MRI investigation at Great Ormond Street Hospital. 
Data from this first follow-up cross-sectional study has been published focusing on aspects 
such as the role of event-related potentials
241 and the detection of brain abnormality using 
MRI-based voxel-based morphometry
199.  
For  the  third  time  point  of  this  cohort,  only  patients  from  Royal  London  hospital  were 
recruited, as part of the R&D approval. Out of 19 patients identified still at Royal London 
hospital,  13  patients  were  recruited.  One  patient  refused  participation  and  five  patients 
could  not  be  contacted.  From  12  original  sibling  controls,  one  sibling  returned,  and  2 
familial controls (i.e. cousins) were also recruited. Demographics are reported in Table 3-4. 
 
2000-2002 East 
London Cohort  
(Royal London) 
n  Age  Gender  Genotype 
Patients  13  18-35 years  8M, 5F  11 HbSS, 2 HbSC 
Controls  3  20-29 years  3M 
2 HbAS,  
1 unknown 
Table  3-4.  Details  of  demographics  for  the  participants  of  the  London  2012-2013  cohort, 
originally from the 2000-2002 East London cohort, recruited from the Royal London hospital.   51 
 
Figure 3-1. Recruitment flow chart diagram for 2012-2013 London Cohort.   52 
3.1.3  Final 2012-2013 London Cohort Sample 
The final sample consists of 61 patients and 23 controls; demographics are report in Table 
3-5 and histogram of age distribution is shown in Figure 3-2.  
 
  n  Age  Gender  Genotype 
Patients  61  8-35 years 
35M, 
26F 
58 HbSS 
3HbSC 
Controls  23  8-29 years 
13M, 
10F 
11 HbAA 
10 HbAS 
2 unknown 
Table  3-5.  Demographics  for  final  2012-2013  London  Cohort  sample,  consisting  of  the 
participants from the 2011 MSc Project and the Longitudinal Project.  
 
 
 
Figure 3-2. Age distribution histogram for final 2012-2013 London Cohort sample, consisting 
of the participants from the 2011 MSc Project and the Longitudinal Project.    53 
3.1.4  MRI Protocol & Radiology 
All  participants  were  scanned  at  Great  Ormond  Street  Hospital  on  a  1.5T  Siemens 
Magnetom Avanto system (Siemens, Erlangen, Germany) with 40mT/m gradients and a 32-
channel receive headcoil. The following sequences were acquired: 
•  T1-weighted Fast Low Angle Shot (FLASH) 3D volume (TR= 11ms, TE= 4.94ms, flip 
angle= 15, voxel size= 1mm
3) 
•  T2-weighted turbo spin echo sequence (TR= 4920ms, TE= 101ms, voxel size= 0.7 x 
0.6 x 4.0mm, slice gap=1.6mm) 
•  Diffusion-weighted  echo  planar  imaging  sequence  (TR=  7300,  TE=  81ms,  voxel 
size= 2.5mm
3, 60 gradient directions, b=1000s/mm
2, 3 interleaved b=0 images). 
All images were visually inspected for artefacts (e.g. movement, dental braces), and certain 
sequences were excluded if necessary. Two independent, experienced neuroradiologists 
(S.B.
‡ ,  T.C.
§ )  read  all  participants’  T2-weighted  MRI  for  lesion  diagnosis.  In  the 
circumstance of conflicting reports, a third neuroradiologist (D.S.
**), read the images blind to 
initial  reports.  Participants  were  excluded  from  analysis  if  no  T2-weighted  image  was 
available (n=2).  
3.1.5  Lesion size analysis 
For the participants in whom abnormal T2s were documented, lesion masks were manually 
drawn  and  deemed  accurate  by  agreement  of  two  neuroradiologists.    Lesion  size  was 
calculated using FMRIB Software Library (FSL)
242; the size of the voxel multiplied by the 
slice gap outputs the volume in mm
3.  
3.2  Cognitive Assessment 
All participants underwent cognitive assessment by trained researchers at the UCL Institute 
of Child Health. Participants were given:  
•  Wechsler Abbreviated Scale of Intelligence (WASI)
243, a standardised abbreviated 
version of the Wechsler Intelligence Scale for Children (WISC-III) and the Wechsler 
Adult  Intelligence  Scale-Third  Edition  (WAIS-III).  In  this  study,  the  two-subtest 
                                                          
‡Simon  Barker  MB  ChB,  MRCP,  FRCR  –  consultant  radiologist  (University  Hospital 
Southampton, UK) 
§Tim Cox MBBS FRCR – consultant radiologist (Great Ormond Street Hospital, London, UK) 
**Dawn Saunders MD FRCR – consultant paediatric neuroradiologist (Great Ormond Street 
Hospital, London, UK)   54 
(vocabulary,  matrix  reasoning)  WASI  is  used,  providing  full-scale  intelligence 
quotient (FSIQ). Scores are scaled for developmental stage, with a mean of 100 and 
standard deviation of 15. The WASI is appropriate for children older than 6. 
Delis-Kaplan Executive Function System (D-KEFS)
244 is a 90-minute battery for people older 
than 8 years, which provides reliable and valid measure of executive functions
245,246. Four 
standalone tests were used: 
•  D-KEFS  Tower  test  measures  strategic  spatial  planning,  rule  learning,  impulse 
inhibition  and  establishing  and  maintaining  cognitive  set.  The  test  requires 
participants to build a series of 9 progressively difficult towers, with a three-pegged 
base  and  5  sizes  of  coloured  discs.  For  each  tower,  the  participant  is  given  a 
prearranged set of disks and a picture of what the finished tower should look like, 
and  instructed  to  build  the  tower  shown  in  the  picture  using  as  few  moves  as 
possible. The rules are that only one hand may move the discs and a larger disc 
cannot be placed on a smaller disc. Total achievement score is based on number of 
moves and number of completed towers within the time limit, and scaled scores are 
reported (mean 10, standard deviation 3).  
  
•  D-KEFS  Trail-making  test  –  visual  scanning  condition  measures  visuomotor 
processing speed and attention. In this task, the subject is presented with an A3 
landscape page with various circles of different numbers and letters, and asked to 
make a single mark through all the circles with the number “3”, as fast as possible 
without making mistakes  (Appendix  A).  Completion  time  is  recorded  and  scaled 
scores are reported (mean 10, standard deviation 3).  
 
•  D-KEFS Trailmaking test – number-letter switching condition requires cognitive 
flexibility,  attentional-set  shifting  and  motor  speed.  In  this  task,  the  subject  is 
presented with an A3 landscape page with various circles of different numbers and 
letters,  and  asked  to  draw  lines  to  connect  circles  with  letters  and  numbers, 
switching  between  letter  and  number  (i.e.  “1-A-2-B-3-C”  etc.;  Appendix  A). 
Completion time is recorded and scaled scores are reported (mean 10, standard 
deviation 3).  
 
•  D-KEFS  Verbal  Fluency  test  –  letter  fluency  condition  measures  systematic 
retrieval of lexical items and processing speed. In this task, the subject is given 60 
seconds to say as many words as he/she can that start with a particular letter (e.g. 
“T”), without giving the names of people’s names (e.g. “Tom”, place names (e.g. 
“Tottenham”) or numbers (e.g. “Twelve). Total score is calculated as the sum of   55 
correct  responses  over  three  sets  of  this  task,  and  scaled  scores  are  reported 
(mean 10, standard deviation 3). 
 
•  D-KEFS Colour-Word Interference – inhibition/switching condition, a version of 
the commonly known Stroop test, measures naming speed, reading speed, verbal 
inhibition and cognitive flexibility. The subject is given a page with names of colours 
written in the same ink colour to the words that are printed, and words written in 
dissonant ink colours to the words that are printed. In this condition, the subject is 
asked  to  switch  back  and  forth  between  naming  the  dissonant  ink  colours  and 
reading the words (Appendix A). Completion time is recorded and scaled scores are 
reported (mean 10, standard deviation 3).  
 
•  The  Behaviour  Rating  Inventory  of  Executive  Functions  (BRIEF)  is  a  parent 
questionnaire for children younger than 18,  consisting  of  86  items in  eight  non-
overlapping behavioural regulation and metacognition clinical scales (Appendix A). 
The Global Executive Composite score takes into account all the clinical scales and 
represents the child’s overall executive function. BRIEF scaled scores are reported 
(mean of 50 and standard deviation of 10), where higher scores represent more 
dysfunction.  
3.3  Additional information 
On the day of the scan, additional information was asked of participants’ guardians (or the 
adult participant himself or herself), regarding handedness, if the participant was on regular 
blood transfusion treatment or hydroxycarbamide treatment, if the participant was taking 
pain medication regularly and how often the participant experienced severe pain episodes, 
including hospitalisations for pain crises. 
3.3.1  Oximetry 
On the day of the MRI, peripheral oxygen saturation data was collected over a 5-minute 
period from a pulse oximeter (Masimo Pronto-7 Pulse CO-Oximeter). This involved making 
sure the participant was seated at rest and was feeling generally well. Data were excluded if 
the participant had false acrylic nails (n=1) or if the pulse oximeter did not produce data 
(n=1).   56 
3.3.2  Haematology 
Clinical  data  from  relevant  medical  records  were  collected  at  the  discretion  of  each 
patient’s  consultant  haematologist.  Dates  of  hospitalisations,  treatment  history  and  full 
blood counts and pulse oximetry readings from clinical notes from up to three years prior to 
MRI were collected. 
3.4  Considerations for Statistical Power 
All  participants  recruited  as  part  of  the  London  2012-2013  originally  had  taken  part  in 
previous studies at the Institute of Child Health/Great Ormond Street Hospital. It is possible 
the sample is limited by a sampling convenience bias and results from this thesis may not 
be representative or generalizable to a greater population of SCD patients.    
Statistical power refers to the ability of a sample size to detect a meaningful effect size 
between groups. If there is inadequate power, one may not be able to detect a difference 
when it actually exists.  
There was no information about past neuroimaging results during the recruitment process; 
due to the nature of clinically silent cerebral infarcts, it was impossible to gauge how many 
participants would be allocated to MRI-defined groups. Although there were no prospective 
sample size or power calculations estimated before recruitment started for this thesis, I 
intended to achieve adequate statistical power by recruiting as many participants possible 
to increase sample size in all groups.  
Statistical  power  for  the  observed  effect  sizes  were  calculated  where  appropriate,  and 
sample size considerations are discussed in context.  
3.5  Conclusion 
This chapter overviewed the methods of participant recruitment, MRI protocol, radiology 
assessment  and  neuropsychological  assessment.  These  methods  underlie  the  following 
four chapters, which will discuss specific analysis and results.      57 
Chapter 4.  Intelligence Quotient in Asymptomatic 
Children with Sickle Cell Disease 
Intelligence  quotient  is  the  most  commonly  reported  and  widely  studied  standardised 
measure  of  cognitive  ability  in  SCD.  Beginning  from  the  late  1980s/early  1990s,  many 
studies  have  reported  patients  having  lowered  global  intelligence  scores  than  matched 
controls,  even  when  excluding  those  with  history  of  stroke  or  abnormal  neurological 
examination
102,213–215,247,248. 
As mentioned in chapter 2, up to 35% of children with SCD will experience at least one SCI 
in the first decade of life, in which there is an abnormality seen on T2-weighted MRI in the 
absence of overt stroke (neurological symptoms lasting more than 24 hours). By definition, 
SCI are clinically silent and therefore age at which SCI occurred and time lapse between 
SCI and cognitive testing are unknown. Presence of SCI has been associated with general 
cognitive  dysfunction
104,  as  well  as  specific  deficits  in  executive  functions,  including 
sustained attention, cognitive flexibility and working memory
217,219,227,232,233.  
The first study that used MRI to classify patients into groups based on whether SCI are 
present  or  absent  was  published  in  1996
104.  Collaborators  in  the  United  States  CSSCD 
linked presence of abnormality on MRI and measurable global cognitive dysfunction.  Since 
then, several studies looking at intelligence have confirmed that children with SCI (SCI+) 
perform  worse  than  those  without  evidence  of  SCI  (SCI-)
199,203,216,218,220,223,  including  one 
CSSCD study that reported presence of SCI was associated with decreases in IQ over a 
period of 8-16 cross-sectional years
220. Some have reported that larger lesion size in SCI+ 
patients is associated with lower FSIQ
221,249, suggesting there may be a threshold of injury 
severity associated with lowered IQ
224.  
There  are  fewer  publications  that  had  included  a  control  population  to  investigate 
differences in IQ between individuals with SCD who have normal MRI and those without 
SCD. These studies are necessary to elucidate differences in neurocognitive outcome that 
may be due to subtle aspects of the disease, such as chronic anaemia and hypoxia
250, and 
attempt to separate them from sociological and environmental effects. Within those studies 
that  have  used  a  control  group,  some  have  used  pseudo-controls  (i.e.  normative 
databases
106,216) that may not be appropriately matched for non-neurological factors known 
to influence intelligence, such as socioeconomic status
251, parental education
252 and school 
absences
220.    58 
4.1  Hypotheses 
The purpose of this chapter is to review the literature on intelligence in relation to SCI and 
other factors in children with SCD. To be eligible for review, the study must have included a 
paediatric SCD population, used MRI to define presence of absence of SCI and/or stroke 
and used a Wechsler intelligence scale measure that reported FSIQ.  
Beyond the review, this chapter also includes previously unreported data from the 2012-
2013  London  cohort,  including  a  sibling  control  group,  which  will  be  used  to  test 
hypotheses based on the review of the existing literature. The following hypotheses are 
tested:  
•  There  is  a  stepwise  progression  of  decreasing  IQ  with  lesion  status:  (i.e.  SCI+ 
patients will have lower FSIQ than SCI- patients, and SCI- patients will have lower 
mean FSIQ than the sibling control group), and  
•  Lesion size in SCI+ patients will correlate with FSIQ.  
4.2  Methods 
Sixteen publications are included in this review (Table 4-1). This review is supplemented by 
48 SCD patients and 19 sibling controls (aged 8-18) from the 2012-2013 London cohort. In 
the patient group, three MRI-defined subgroups were identified from T2-weighted MRI:  
•  Those with previous history of stroke (n=4; all male; mean age: 15.44 years ± 3.02),  
•  Those with evidence of SCI (n=13; 8 male; mean age: 14.14 years ± 2.48), and  
•  Those with no evidence of SCI (n=31, 16 male; mean age: 13.29 years ± 2.70).  
4.2.1  Statistical Analysis 
To test differences between groups, an analysis of variance was performed. A post-hoc 
least significant difference (LSD) that uses t-tests for pairwise comparisons between group 
means was used. Bivariate Pearson’s r correlations were performed between lesion size 
and FSIQ.   59 
4.3  Results  
4.3.1  FSIQ Scores Across All Studies 
All sixteen studies included SCI- and SCI+ groups, six studies included a group with history 
of stroke, and six included a control group (Table 4-1 and Figure 4-1). 
All studies that reported FSIQ in stroke patients found scores were considerably lower than 
other groups of SCD patients; four of six studies reported significantly lower scores
104,219–221. 
Mean  FSIQ  in  those  with  stroke  ranged  from  65.9
221  to  76.9
220,  almost  two  standard 
deviations lower than the healthy population mean derived from Wechsler manuals. 
For the patients with evidence of SCI, mean FSIQ scores ranged from 70.6
216 to 93.12
252. 
Four studies showed SCI+ patients had a significantly lower FSIQ scores than SCI- patients 
(effect sizes ranged -0.56 - -0.79)
199,216,220,252, and one study with a nonsignificant difference 
between SCI+ and SCI- also showed a moderate effect size of -0.61
217. However, four other 
studies found no statistical difference between SCI+ and SCI- patients with small effect 
sizes of -0.23
218, -0.45
253, 0.29
188 and -0.08
231.  
Six studies included in this literature review included a control group (Table 1, Figure 4-2). 
Two studies that used a normative database of matched controls found SCI- patients to 
have  significantly  lower  mean  FSIQ,  with  moderate  to  large  effect  sizes  (-0.63
216  and  -
0.99
106).  The  remaining  four  studies  recruited  matched  controls  contemporaneously  with 
patients. Two studies used a sibling group
217,218, one study used a control group in which 
half  of  the  total  participants  were  siblings
199,  and  one  study  used  age-,  gender-  and 
socioeconomic status-matched controls
221.  
Of the two studies that used a sibling control group, one found a nonsignificant 6-point 
lower mean FSIQ in patients than controls with an effect size of -0.5
217 and the other found 
SCI- patients had a 4-point reduction in FSIQ; although but statistical difference was not 
tested
218. The effect size was calculated as -0.23.  
Of the other two studies, one with 39% (12/31) sibling controls found a significant 9-point 
difference in FSIQ with an effect size of -0.73
199. Finally, in the study using a matched, non-
sibling  control  group,  there  was  a  nonsignificant  3-point  reduction  in  the  SCI-  group 
compared to controls (effect size of 0.26)
221. 
None of these studies analysed the relationship between lesion volume in SCI+ patients and 
FSIQ.   60 
Author(s) 
Patient 
Group 
Patient 
Subgroups 
Control 
Group 
Battery 
Control 
FSIQ: 
mean (sd) 
SCI- FSIQ: 
mean (sd) 
SCI+ 
FSIQ: 
mean (sd) 
Stroke 
FSIQ: 
mean (sd) 
Notable Findings 
Armstrong 
et al. (1996) 
 
HBSS/HbSC 
(n=194) 
 
n=9 stroke 
n=24 SCI+ 
n=161 SCI- 
none  WISC-R  N/A  90 (1.7)  82.8 (2.9)  70.8 (5) 
Stroke < SCI+ (FSIQ, PIQ) 
Stroke < SCI- (FSIQ, PIQ, VIQ) 
Steen et al. 
(1998) 
SCD (n=22) 
n=10 SCI+ 
n=12 SCI- 
n=30 from 
“historical 
data of 
healthy 
siblings” 
WISC-R 
WISC-III 
88 (16.1)  78.9 (8.9)  70.6 (12.1)  N/A 
SCI+ < SCI- and controls (FSIQ) 
SCI- < controls (FSIQ) 
controls < population mean 
Watkins et 
al. (1998) 
SCD (n=39) 
n=5 stroke 
n=4 SCI+ 
n=30 SCI- 
n=15 sibling 
controls 
WISC-III 
WPPSI-
R 
92.07 
(12.2) 
86.03 (12)  79 (5.7)  67.6 (16.6) 
Stroke < SCI- and controls (VIQ, PIQ, 
FSIQ) 
SCI+ < SCI- < controls (nonsignificant) 
Bernaudin 
et al. (2000) 
SCD (n=173) 
n=12 stroke 
n=20 SCI+ 
n=101 SCI- 
n=76 sibling 
controls 
WISC-III 
WPPSI-
R 
90.3 (14.3)  86.6 (17.1)  82.6 (15.7)  73.5 (14.4) 
SCI+ < SCI- (VIQ) 
*no statistical comparison between 
SCI- and controls. 
Brown et al. 
(2000) 
HbSS/HbSC 
(n=63) 
n=22 stroke 
n=11 SCI+ 
n=30 SCI- 
none  WISC-III  N/A 
81.67 
(16.68) 
81.91 
(14.43) 
75.05 
(15.53) 
Stroke < SCI+ and SCI- 
Wang et al. 
(2001) 
HbSS 
(n=185) 
n=20 stroke 
n=43 SCI+ 
n=122 SCI- 
none 
WISC-R 
WISC-III  N/A  84.8 (13.5)  77.2 (13.7)  76.9 (17.2) 
Stroke < SCI+ and SCI- (FSIQ, VIQ, 
PIQ) 
SCI+ < SCI- (FSIQ, VIQ)   61 
Author(s) 
Patient 
Group 
Patient 
Subgroups 
Control 
Group 
Battery 
Control 
FSIQ: 
mean (sd) 
SCI- FSIQ: 
mean (sd) 
SCI+ 
FSIQ: 
mean (sd) 
Stroke 
FSIQ: 
mean (sd) 
Notable Findings 
Schatz et al. 
(2002) 
HbSS (n=27) 
n=18 SCI+ 
n=9 SCI- 
none  WASI  N/A  89.9 (7.9)  81.9 (12.4)  N/A 
*no statistical comparison between 
SCI+ and SCI- 
Larger lesion volume associated with 
lower FSIQ 
Steen et al. 
(2003) 
HbSS (n=49) 
n=16 SCI+ 
n=33 SCI- 
none 
WISC-R 
WISC-III 
N/A  81.1 (11)  78.6 (16.1)  N/A 
In patients, FSIQ decreased with age 
SCI+ < SCI- (VIQ) 
Steen et al. 
(2005) 
HbSS (n=54) 
n=24 SCI+ 
n=30 SCI- 
standardised 
matched 
sample from 
the WISC-III 
WISC-III 
91.37 
(12.19) 
79.4 (11.9) 
excluded 
from 
analysis 
N/A  SCI- < controls (FSIQ) 
Baldeweg et 
al. (2006) 
HbSS/HbSC 
(n=36) 
n=16 SCI+ 
n=20 SCI- 
n=31 (12 
siblings) 
WISC-III 
WAIS 
101 (11)  92 (14)  82 (13)  N/A 
SCI+ < SCI- (FSIQ, VIQ, PIQ) 
SCI- < controls (FSIQ, VIQ) 
Hogan et al. 
(2006) 
SCD (n=30) 
n=17 SCI+ 
n=13 SCI-  none 
WISC-III 
WAIS-R  N/A  87.4 (8.1)  82.5 (12.5)  N/A 
No difference between SCI+ and SCI- 
(FSIQ)  
Kral et al. 
(2006) 
HbSS (n=27) 
n=5 SCI+ 
n=22 SCI- 
none  WASI  N/A 
87.59 
(11.42) 
90.60 
(3.05) 
N/A 
No different between SCI+ and SCI- 
(FSIQ) 
Negative association between 
chronologic age and FSIQ 
Schatz & 
Buzan 
(2006) 
HbSS (n=28) 
n=8 stroke 
n=8 SCI+ 
n=12 SCI- 
n=16 
matched 
controls 
WISC-III  97.9 (11.8)  94.5 (14.2)  92.9 (12.8)  65.9 (14.8)  Stroke < SCI- and controls (FSIQ)   62 
Author(s) 
Patient 
Group 
Patient 
Subgroups 
Control 
Group 
Battery 
Control 
FSIQ: 
mean (sd) 
SCI- FSIQ: 
mean (sd) 
SCI+ 
FSIQ: 
mean (sd) 
Stroke 
FSIQ: 
mean (sd) 
Notable Findings 
Hijmans et 
al. (2011) 
HbSS/HbS β-
thalassaemia 
(n=34) 
n=12 SCI+ 
n=9 SCI- 
none  WISC-III 
WAIS-III 
N/A  80 (9)  79 (14.4)  N/A  No difference between SCI+ and SCI- 
(FSIQ) 
Hollocks et 
al. (2012) 
HbSS (n=10) 
n=1 SCI+ 
n=9 SCI- 
none  WASI  N/A  87 (16.12) 
Excluded 
from 
analysis 
N/A  SCI- FSIQ in the low average range 
King et al. 
(2014) 
HbSS/HbS β-
thalassaemia 
(n=150) 
n=107 SCI+ 
n=43 SCI-  none 
WASI 
WPPSI-
III 
N/A 
100.53 
(13.08) 
93.12 
(12.5)  N/A 
SCI+ < SCI- (FSIQ) 
Negative association between 
chronologic age and FSIQ 
2012-2013 
London 
cohort 
(previously 
unreported) 
HbSS/HbSC 
(n=64) 
n=31 SCI- 
n=13 SCI+ 
n-4 stroke 
n=19 sibling 
controls 
WASI 
WASI-II 
107.79 
(11.78) 
99.81 
(13.48) 
93.46 
(10.70) 
96.75 
(8.62) 
SCI+ and SCI- < Controls 
No significant difference between SCI+ 
and SCI- 
No correlation between lesion size and 
FSIQ or age 
WISC, Wechsler Intelligence Scale for Children; WISC-R, Wechsler Intelligence Scale for Children-Revised; WPPSI-R, Wechsler Preschool and Primary 
Scales of Intelligence - Revised; WASI, Wechsler Abbreviated Scale of Intelligence; WAIS, Wechsler Adult Intelligence Scale 
 
Table 4-1. Review of FSIQ literature in paediatric SCD using MRI-defined groups.   63 
 
 
 
 
Figure  4-1. Review of FSIQ literature in paediatric SCD using MRI-defined groups. Horizontal black lines represent mean FSIQ of the entire group, including 
previously unreported data from the 2012-2013 London cohort. Italicised numbers on x-axis indicate number of subjects in each group. 
     64 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  4-2. Review of FSIQ literature in paediatric SCD using MRI-defined groups, in which only studies that used non-SCD control groups were included. 
Horizontal black lines represent mean FSIQ of the entire group, including previously unreported data from the 2012-2013 London cohort. Italicised numbers on x-
axis indicate number of subjects in each group.   65 
4.3.2  Previously Unreported Data 
FSIQ results from the 2012-2013 London Cohort sample are reported in Table 4-2. Mean 
FSIQ for the control group was 107.79 ± 11.78, for the SCI- patient group was 99.81 ± 
13.48, for the SCI+ patient group was 93.46 ± 10.70, and for the stroke patient group was 
96.75 ± 8.62.  Figures 4-1 and 4-2 show a graphical representation of the current study 
group means in relation to the previously reported data from sixteen studies under review. 
While the SCI- and SCI+ groups’ data fall within the range of previously reported FSIQ of 
similar groups, the sibling control group mean is higher than previous studies, and 7 points 
higher  than  the  population  mean.  The  SCI-  and  SCI+  group  means  are  within  normal 
intelligence ranges. Similarly, the stroke group mean FSIQ is nearly 20 points higher than 
the  highest  previously  reported  data,  although  there  are  only  4  patients  comprising  the 
group. 
The  stroke  group  was  excluded  from  further  analysis  due  to  low  subject  numbers.  An 
analysis  of  variance  showed  significant  differences  between  the  three  groups  (controls, 
SCI-, SCI+: ANOVA F=5.335, p=0.007), with the controls group having significantly higher 
FSIQ than the SCI- group (7.98 mean point difference; t=2.129, p=0.032, effect size= 0.62) 
and the SCI+ group (14.33 mean point difference; t=3.505, p=0.002, effect size=1.26). There 
was no significant difference between the SCI- and SCI+ groups (t=1.506, p=0.140, effect 
size=0.50). (Table 4-2) 
 
 
Control  SCI-  SCI+ 
 
p 
n  19  31  13 
   
Genotype 
11 HbAA  
8 HbAS 
31 HbSS 
12 HbSS 
1 HbSC     
Age  12.72 ± 3.12  13.29 ± 2.70  14.14 ± 2.48  ANOVA 
F=0.947 
p=0.394 
Gender  9M, 10F  16M, 15F  8M, 5F  χ
2=0.636  p=0.728 
FSIQ  107.79 ± 11.78  99.81 ± 13.48  93.46 ± 10.70  ANOVA 
F=5.335 
p=0.007
b,c 
aSCI+ < SCI-, 
bSCI+ < Controls, 
cSCI- < Controls 
Table 4-2. Demographics and FSIQ scores of the 2012-2013 London cohort. 
 
Although  the  difference  in  means  was  significant  (p=0.032)  between  control  and  SCI- 
groups, the statistical power for the moderate effect size (d=0.62) was 55%. In order to 
achieve 80% power, 42 participants would have been required in each group.     66 
There  was  no  significant  difference  in  means  between  the  SCI-  and  SCI+  groups.  The 
statistical power for the moderate effect size (d=0.50) was 32%; 64 participants would have 
been required to achieve 80% power. 
4.3.3  Lesion size and FSIQ 
In the SCI+ subjects, lesion size and FSIQ data are shown in Table 4-3. The locations of the 
lesions varied: 69% (9/13) had lesions in the frontal lobe, 54% (7/13) in the parietal lobe, 
and 46% (6/13) had lesions in more than one lobe. Two patients had lesions in subcortical 
regions (head of caudate, cerebellum). One extreme outlier (Subject 13) was excluded from 
lesion size analysis due to diffuse lesions. In the remaining 12 SCI+ patients, there was no 
significant correlation between lesion size and FSIQ (r=0.068, p=0.833) or age (r=-0.188, 
p=0.558).  
 
  Gender  Age 
(years) 
Lesion Location  Lesion Size 
(mm
3) 
FSIQ 
1  M  16.49  L Frontal  41.36  104 
2  M  12.94  R Frontal  58.82  89 
3  M  10.64  R Corpus Callosum  64.33  104 
4  M  18.58  Bilateral Cerebellar, L 
Parietal 
91.69  92 
5  M  12.86  L Head of Caudate  108.45  95 
6  F  17.90  R Frontal  128.67  94 
7  M  12.56  L Parietal and Frontal  147.71  72 
8  F  16.77  R Parietal and Frontal  189.33  97 
9  F  14.02  R Parietal and Frontal  205.87  88 
10  F  12.47  R Parietal  275.72  107 
11  M  12.01  Bilateral Frontal, L Parietal  443.82  76 
12  F  13.93  Bilateral Frontal  755.46  105 
13  M  12.69  Bilateral Frontal and 
Parietal, Left Occipital 
11449.58  92 
Table 4-3. Lesion size and location of SCI+ patients.    67 
 
Figure  4-3. Lesion size and FSIQ plot. There was no significant correlation between size of 
lesion (mm
2) and full-scale IQ in 12 SCI+ patients. 
 
4.4  Discussion 
The results from the previously unreported data are in line with aforementioned research: 
both SCD patients with or without SCI have significantly lower FSIQ than sibling controls. 
Further, this study found no significant difference in FSIQ between patients with or without 
SCI, although there was a moderate effect size suggesting that patients with SCI performed 
worse than those without. These results suggest that presence of lesions, or lesion size 
alone,  may  not  account  for  differences  in  general  cognitive  ability,  and  other  mediating 
factors potentially relating to the disease process could play a role.  
4.4.1  Neuroimaging Correlates of IQ 
There has been some groundwork in finding neuroimaging correlates of intelligence in the 
paediatric SCD literature. One study split patients into a high- and low-IQ group, using the 
Kaufman’s  Brief  Intelligence  Test;  the  authors  found  children  in  the  low-IQ  group  had 
smaller grey matter volume in bilateral frontal, temporal and parietal lobes compared to the 
high-IQ group
201. Schatz and Buzan
221 found that the size of the corpus callosum on the 
midsagittal section was reduced in patients with SCI compared to those without, but the 
size of the corpus callosum provided no explanatory power for general cognitive function. 
However, these studies did not take into account any factors known to influence both brain   68 
morphometry and IQ. In contrast to a report of poor correlation between TCD velocity and 
FSIQ
238, a strong, inverse correlation has been found between performance IQ and FSIQ 
and bilateral cerebral blood flow (CBF) by perfusion MRI
254, with the strongest association 
between anterior and right-sided CBF and performance IQ. The authors suggest measures 
of performance IQ may be sensitive to global oxygen delivery. 
4.4.2  Effect of chronic disease on IQ 
Previous  studies  have  shown  SCD-related  markers  of  disease  severity  to  correlate  with 
intelligence.  There  have  been  links  with  anaemia  severity
194,218,223,236;  more  specifically, 
haematocrit
194,218 and the interaction between age and haematocrit
188, that have also been 
shown in non-SCD populations
255–257. This correlation between anaemia and IQ could be 
due to a direct impact on the brain (i.e.  anaemia-induced  hypoxia/ischaemia)  or  due  to 
indirect  influences  on  processes  such  as  the  body’s  response  to  anaemic  hypoxia 
exposure
258,  which  leads  to  increased  cerebral  blood  flow
259–261  and  cerebral  blood  flow 
velocity
180,253, reduction in cerebrovascular reserve
91 and subsequent large and small vessel 
injury/ischaemia
92. Chronically altered cerebral circulation may lead to a cycle of long-term 
hypoxia
194 and cognitive dysfunction
262. Other SCD-related biomarkers previously linked to 
cognitive outcome include growth delays
263, possibly linked to poor nutrition
215, that may 
have an effect on the development and maturation of the brain
200,221.  
4.4.3  Effects of Silent Infarction on IQ  
Children  with  evidence  of  SCI  on  MRI  have  long  been  reported  to  have  cognitive 
dysfunction
216,220,264,  and  the  discrepancy  in  FSIQ  between  SCI+  and  SCI-  patients  is 
approximately 4-7 points
104,218,220. Drawing a parallel with the hypothesised pathophysiology 
in elderly adults in the general population, SCI in children with SCD are considered to be 
secondary to small vessel disease, in which white matter in the frontal lobe borderzones 
between the anterior and middle cerebral arteries is most affected
78. However, in general, it 
is difficult to control for the effects of unilateral/bilateral infarction, number of infarcts and 
when they occurred. In a study looking specifically at the influence of lesion burden on 
intelligence
224, small infarct volume appeared to have minimal impact on global cognitive 
ability but larger volume was associated with lowered FSIQ scores in eight patients with 
SCI. This study suggests there may be a threshold of lesion size before IQ is affected. Our 
results  with  a  slightly  larger  sample  size  of  twelve  indicate  no  significant  relationship 
between  quantitative  lesion  size  and  FSIQ.  While  all  of  the  patients  had  relatively  small 
lesions, one patient had very large, diffuse lesions, yet with an IQ still in the normal range. 
As Schatz and colleagues
224 suggest, only a longitudinal study in a large group of paediatric   69 
SCD patients with SCI could demonstrate if SCI is associated with progressive decline in 
IQ.  
The data from SCI+ patients in this sample are typical of previous reported studies: small 
sample  size  and  unknown  information  such  as  age  when  SCI  occurred  and  time  lapse 
between  study  MRI  and  age  when  SCI  occurred.  It  is  likely  that  patients  experience 
repeated infarction
78,265,  and  large  lesion  size  due  to  one  event  or  repeated  events  may 
result in different cognitive profiles. 
Other populations also experience SCI in childhood due to chronic conditions. People with 
obstructive sleep apnoea or people living in high-altitude locations may have white matter 
abnormality
266  and  cognitive  dysfunction
267–269.  Obstructive  sleep  apnoea  can  also  be 
comorbid with SCD
270,271, which may exacerbate hypoxia.  
One  study  described  worsening  cognitive  performance  with  presence  of  periventricular 
hyperintensities in patients with obstructive sleep apnoea
272, but to date, no studies have 
explicitly  investigated  the  relationship  between  size  of  lesion  and  cognition  in  those 
conditions. 
4.4.4  Effect of Age on IQ 
There was one finding in this study that was not related to the original study hypotheses yet 
worthy of consideration. In a meta-analysis, Schatz and colleagues
114 suggested there is 
evidence of cognitive effects worsening with age. Included in the review, they found some 
studies reporting older children performing worse than younger children
113,210,220, but others 
not  finding  that  pattern
194,211,213,214,247.  More  recent  reports  did  find  a  significant  negative 
association with FSIQ and age in combined SCI- and SCI+ patients
188,221,252. The results 
from the current study show a negative, but nonsignificant, correlation between age and 
FSIQ in patients (excluded n=4 stroke; r= -0.209, p= 0.173). When divided into MRI-defined 
groups, there was a positive, trend-level correlation between age and FSIQ in the SCI+ 
group (r= 0.141, p=0.065), but a negative, but nonsignificant correlation in the SCI- group 
(r= -0.277, p= 0.131). It is difficult to interpret positive and negative associations between 
age and FSIQ. A positive association could reflect longer time of recovery post-injury and 
perhaps  an  effect  of  treatment  with  hydroxycarbamide  or  regular  blood  transfusion  for 
patients  with  SCI,  while  a  negative  association  could  reflect  a  longer  time  exposed  to 
chronic hypoxia and subacute brain damage associated with acute hypoxic events such as 
pain crises or acute chest syndrome
113.    70 
4.4.5  Statistical considerations 
For the significant difference in IQ between Control and SCI- groups, statistical power was 
calculated  as  55%.  This  implies  that  in  replicated  studies  of  the  same  sample  size  of 
different participants, a significant result will only be found 55% of the time. For the non-
significant  difference  in  IQ  between  SCI-  and  SCI+  groups,  it  is  likely  the  study  was 
underpowered  (32%  power  calculated)  and  significant  differences  may  be  found  by 
increasing sample size, in line with recent literature
252. 
The exploratory correlation between lesion size and IQ was non-significant and had very 
low statistical power. It is possible the population correlation is actually close to zero or the 
sample size is far too small and the test required a far larger number of participants.    
4.4.6  Limitations 
This addition to the study is limited by not including details of socioeconomic status and 
parental  education  in  the  analysis,  both  widely  accepted  to  influence  a  child’s  IQ 
performance
113,114,220,252.  This  analysis  used  a  sibling  control  group  to  control  for  those 
factors.  However,  that  information  is  important  to  know  to  understand  how  the  social 
context  of  the  child  interacts  with  the  disease  process
114  to  adequately  understand  the 
cause of cognitive deficits in children without abnormal MRI findings. 
Full-scale IQ was the only measure of cognitive ability discussed in this chapter because 
historically  it  has  been  the  most  widely  studied.  In  this  review,  including  previously 
unreported data, FSIQ was obtained from the versions of the WASI in four studies and the 
versions of the WISC in seven studies. While the WASI gives a brief measure of FSIQ from 
two or four subtests, the WISC FSIQ is made up of ten verbal and performance subtests.  
Although WASI FSIQ and WISC FSIQ are correlated
243, it is possible that FSIQ is too broad 
a measure to disentangle specific, subtler cognitive functions. While the Wechsler scales 
are a reliable measure of general cognitive ability, some argue that they fail to relate to real-
world  performance
273.  Academic  achievement  may  be  a  more  appropriate  outcome 
measure; children with SCD suffer a chronic illness and exhibit poor school attendance, 
recurrent  hospitalizations  and  economic  hardship
80,220,236,251,274,275,  in  which  functional 
impairment can endure into adulthood
276. 
4.5  Conclusion 
This chapter reviewed the FSIQ literature in paediatric SCD studies that have used MRI-
defined groups to determine differences between patients with or without SCI. Although the   71 
differences  in  intelligence  between  those  with  and  without  SCI  have  been  more  widely 
studied,  the  results  from  this  chapter  added  to  a  gap  in  the  literature  regarding  the 
differences between those children with no evidence of SCI and an appropriately matched 
sibling  control  group:  SCD  patients  with  and  without  SCI  perform  worse  than  sibling 
controls, although no statistical differences in FSIQ were found between SCI+ and SCI- 
patients.  
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Chapter 5.  Subcortical and Cerebellar Volumetric 
Differences in Sickle Cell Disease 
Previous studies have shown structural neuroanatomical differences between patients with 
evidence  of  silent  cerebral  infarcts  (SCI+),  patients  without  lesions  (SCI-)  and  healthy 
controls. A voxel-based morphometry study showed that in SCI+ patients, there is evidence 
of bilateral white and grey matter density decreases in areas corresponding to the arterial 
borderzone distribution
199. Similar white and grey matter density decreases were found in 
SCI- patients compared to controls, but those results were not as widespread and also 
nonsignificant. In a cohort of two groups of SCI- paediatric patients, one study reported 
significant  cortical  thinning  in  older  children  as  compared  to  younger  patients  in  the 
posterior medial surfaces of both hemispheres
202. Decreased grey matter volume in bilateral 
frontal,  temporal  and  parietal  lobes  was  also  found  to  correlate  with  low  IQ  in  SCI- 
children
201.  
Two studies have focused on subcortical grey matter. One found reduced volume of the 
caudate head
195, while the other found reduced volume of central grey matter (i.e.  total 
basal ganglia volume)
200, but none have reported on specific subcortical volumes. 
There is reason to hypothesize volumetric deficits in subcortical grey matter. SCD has been 
described as a model of diffuse brain injury, damaged by chronic anaemia and hypoxia
194. 
Inadequate oxygenation of brain tissue is compensated for my increasing cerebral blood 
flow
204,259,260,277 and dilation of the cerebral vasculature. When metabolic demands increase, 
there may not be enough reserve to ensure sufficient oxygenation, rendering the child at 
high  risk  for  cerebral  ischaemia.  Subcortical  structures,  such  as  the  hippocampus,  are 
particularly vulnerable to hypoxia
278,279.  
5.1  Hypotheses 
This  chapter  focuses  on  grey  matter  volumetric  differences  in  specific,  parcellated 
subcortical structures. An original report describing a cross-sectional analysis of the East 
London  cohort  scanned  between  2001-2002,  which  has  been  published  in  the  British 
Journal of Haematology in 2013
280, is located in Appendix B.  
This chapter extends that previously reported data by including a follow-up analysis of a 
larger cohort of children and adults with SCD. By combining recent and retrospective data 
acquired over a ten-year period, this chapter intends to: confirm volumetric deficits in a 
step-wise progression according to radiological status (i.e. SCI+ patients have most volume   73 
loss, followed by SCI- patients and controls), establish the natural history of subcortical 
volumetric development as a function of age, and determine any relationship with measures 
of general intelligence. 
5.2  Details of Sample 
Data from patients and controls aged 6-30 years were collected from:  
•  East  London  2000-2002  retrospective  cohort,  described  previously
199,241,280  in 
Chapter 3: (33 patients, 21 controls)  
•  London centre of the Silent Infarct Transfusion (SIT) trial screening MRI
160, scanned 
between 2005-2007, described previously in Chapter 3: (26 patients)  
•  Prospective  2012-2013  London  Cohort,  described  previously  in  Chapter  3:  (45 
patients, 21 controls) 
•  Healthy controls from on-going studies at Great Ormond Street Hospital/Institute of 
Child Health, scanned contemporaneously with the 2012-2013 London cohort: (28 
controls) 
5.2.1  Duplicate data 
Some patients who were part of the original 2000-2002 East London cohort returned as 
part of the 2012-2013 London Cohort, scanned approximately 10 years after the original 
study. Similarly, some patients who were screened, but not randomised to the SIT trial 
returned as part of the 2012-2013 London cohort, scanned approximately 5-7 years after 
the original trial screening MRI. In total, 14 adolescents and adults returned; only the most 
recent datasets were included.  
5.2.2  Final Sample 
The final dataset included HbSS and HbSC genotypes, and was comprised of 69 controls, 
56 SCI- patients 28 SCI+ patients.  
Figure 5-1 shows a graphical representation of subject inclusion and exclusion. Individual 
subjects were excluded if there was history of overt stroke at time of scan, presence of 
ischaemic lesions in subcortical grey matter areas on T2-weighted MRI and poor quality 
data/failed  subcortical  segmentation.  Figure  5-2  shows  graphically  the  distribution  of 
subjects’ age and gender overlaid on age boxplots.   74 
 
Figure 5-1. Subject inclusion and exclusion flowchart for volumetric analysis.   75 
 
Figure 5-2. Distribution of age and gender by group of the final sample for volumetric analysis. 
 
5.2.3  Cognitive Assessment 
A measure of full-scale IQ was collected to analyse relationships between intelligence and 
volumes  of  subcortical  structures.  Only  data  from  the  2-subtest  WASI-I  or  WASI-II  was 
included, available from the 2012-2013 London Cohort (30 SCI- patients, 13 SCI+ patients, 
21 controls) and an additional 16 control subjects supplemented to the study. Cognitive 
data from the retrospective East London cohort was excluded because only the WISC-III 
was available and the time lapse between recent and remote cognitive testing was too long 
to ensure reliable results. 
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5.3  MRI Investigation 
MRI was performed over a 10-year period at Great Ormond Street Hospital, in which three 
1.5T MRI scanners were used.  
5.3.1  2000-2002 East London Cohort MRI acquisition 
As described previously for the 2000-2002 East London cohort
199,253,280, 25 patients and 20 
controls were scanned on the 1.5T Siemens Vision system (Siemens, Erlangen, Germany). 
Sequences included:  
•  Axial T2-weighted turbo spin-echo sequence  
o  TR: 3458ms, TE: 96ms, voxel size: 7.5 x 0.43 x 0.43mm)  
•  T1-weighted three-dimensional Fast Low Angle Shot (FLASH) sequence  
o  TR: 16.8 milliseconds, TE: 5.7 milliseconds, flip angle: 21 degrees, voxel 
size: 1.0 x 0.8 x 0.8mm.  
Concurrently with scanning, a consultant paediatric neuroradiologist evaluated all images 
and determined whether SCI were present. All MRIs of SCA without lesions were reviewed 
a second time, jointly with a second consultant paediatric neuroradiologist to confirm the 
initial evaluation. 
5.3.2  Non-randomised SIT trial (2005-2007) MRI acquisition 
Ten patients from the non-randomised SIT cohort were scanned between 2005-2007 on the 
1.5T Siemens Symphony scanner (Siemens, Erlangen, Germany). Sequences included:  
•  Axial T2-weighted turbo spin-echo sequence  
o  TR: 5000ms, TE: 100ms, voxel size: 5.0 x 0.9 x 0.9mm  
•  T1-weighted Fast Gradient Echo sequence  
o  TR: 1900ms, inversion time: 1100ms, TE: 4.15ms, flip angle: 15 degrees, 
voxel size: 1.25 x 1.0 x 1.0mm.  
5.3.3  Additional controls MRI acquisition 
MRI  acquisition  for  the  forty-nine  patients  and  21  controls  from  the  2012-203  London 
Cohort has been previously described in Chapter 3. An additional 28 controls from on-going 
studies at the Institute of Child Health/Great Ormond Street Hospital were scanned using 
the same sequences.    77 
As  mentioned  in  Chapter  3  of  this  thesis,  two  independent  neuroradiologists  read  non-
randomised SIT screening MRI and all subjects’ MRI from the 2012-2013 London cohort to 
determine  whether  SCI  were  present,  and  a  third  neuroradiologist  over-read  for 
discrepancies. Of the twenty-nine SCI+ patients, eleven had left-hemisphere, ten had right-
hemisphere and eight had bilateral infarcts. Twenty-three (79%) had frontal lobe infarcts. 
5.4  Volumetric Analysis 
Automatic  subcortical  volumetric  segmentations  were  analysed  using  Freesurfer  image 
analysis  suite  v5.1  for  Mac  OS  X,  documented  at  the  website:  
https://surfer.nmr.mgh.harvard.edu.  This  software  has  been  described  in  technical  detail 
previously
281–287. For each individual dataset, Freesurfer inputs whole-head high-resolution 
T1-weighted images. The software pipeline includes: motion correction
288, removal of non-
brain  tissue  using  a  hybrid  watershed/surface  deformation  procedure
287,  automated 
Talairach transformation, segmentation of subcortical white matter and deep grey matter 
structures
282,284,  intensity  normalisation
289,  and  steps  that  continue  processing  to  include 
grey  and  white  matter  surface  reconstruction.  Specifically  for  the  automatic  subcortical 
segmentation  processing  stage,  Freesurfer  performs  six  steps:  linear  registration  to  the 
Gaussian  Classifier  Atlas,  canonical  normalisation  and  registration,  registration  and 
subcortical labelling of individual structures
282.  
To minimize methodological errors, each dataset was visually inspected for data quality. 
Subcortical volumes that were assessed included left and right cerebellar cortex, left and 
right thalamus, left and right caudate, left and right putamen, left and right pallidum, left and 
right hippocampus, left and right amygdala, left and right accumbens, and total subcortical 
grey  matter  volume  (Figure  5-3).  Intracranial  volume  was  also  collected  from  Freesurfer 
output for statistical analysis. 
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Figure  5-3.  Freesurfer  subcortical  segmentation  output.  Coronal  (left)  and  axial  (right)  images  showing  most  of  the  structures  analysed,  except  for  nucleus 
accumbens and cerebellar cortex. Total subcortical grey matter volume is a summation of the eight structures.    79 
5.5  Statistical Analysis  
All statistical analyses was performed in R. Subcortical structures from Freesurfer output 
were tested for significant deviations from a normal distribution using Shapiro-Wilk tests. An 
analysis of covariance (ANCOVA) was performed to control for age, gender and intracranial 
volume against subcortical volume variables in the three groups, and p-values corrected 
across variables to control the false discovery rate (with p<0.05 considered significant). The 
Tukey-Kramer  method  was  used  to  perform  post-hoc  tests  to  determine  which  groups’ 
means were significantly different from one another. 
For each group, two Pearson’s correlations were carried out between residual data of each 
subcortical volume (corrected for intracranial volume and gender) with age and FSIQ. 
5.6  Results 
Demographics are reported in Table 5-1. There was a significant difference in age between 
the three groups (ANOVA; F=3.238, p=0.042); mean age of controls was significantly higher 
than the SCI- group (t=2.580, p=0.011). There were no differences in gender ratio between 
the groups. There was a significant difference in FSIQ score between the three groups; the 
control group had significantly higher IQ scores than both patient groups, but there was no 
difference between SCI- and SCI+ groups. 
 
  Control (n=69)  SCI- (n=56)  SCI+ (n=28)   
Age in 
years 
mean (sd) 
17.12 (5.95) 
range: 7.39-
29.42 
14.51 (5.17) 
range: 6.81-
28.43 
16.14 (6.09) 
range: 9.19-
28.65 
ANOVA F=3.238, p=0.042 
post-hoc: controls > SCI- 
(t=2.58, p=0.011) 
Gender  32M, 27F  35M, 21F  15M, 13F  χ2= 3.231, p=0.199 
Genotype 
59 HbAA  
10 HbAS 
51 HbSS 
 5 HbSC 
27 HbSS  
1 HbSC   
FSIQ* 
mean (sd) 
111.54 (14.43) 
98.57 
(13.18) 
92.69 
(10.74) 
ANOVA F=12.837, p<0.0005 
post-hoc: controls > SCI- 
(p=0.0005) 
controls > SCI+ (p=0.0005) 
SCI- > SCI+ (p=0.192) 
 
*FSIQ was available for 37 controls (21 familial controls), 30 SCI- patients, 
and 13 SCI+ patients. 
Table 5-1. Demographics of final sample for volumetric analysis.      80 
5.6.1  Group Differences 
ANCOVA results are summarised in Table 5-2. Figure 5-4 shows a graphical representation 
of the group means in those measures that were significantly different between groups, 
after correction for multiple comparisons. After correcting for the effects of age, gender and 
intracranial volume, volumes for total subcortical grey matter volume, bilateral cerebellar 
cortices,  bilateral  amygdalae  and  right  putamen  were  significantly  different  between  the 
three groups. 
For total subcortical grey matter volume, controls had significantly greater mean volume 
than both the SCI- and SCI+ groups. Similarly, for the bilateral cerebellar cortices and left 
amygdala, controls had significantly greater mean volumes than both the SCI- and SCI+ 
groups. For the right amygdala, the control group had significantly greater mean volume 
than the SCI- group. In the right putamen, controls and the SCI- group had significantly 
greater mean volumes than the SCI+ group, although there was no statistical difference 
between controls and SCI-. For all these significant results, moderate to large effect sizes 
were found (Table 5-2). Statistical power for the effect sizes ranged from 69-97%. The left 
hippocampus  showed  trend-level  differences  between  Control  and  SCI+  groups  (effect 
size= 0.54 with 70% statistical power). In order to achieve 80% power for the same effect 
size, 31 SCI+ patients would have been needed. 
These results are in line with previously reported data from the 2000-2002 East London 
cohort, which reported a general trend of decreasing means corresponding to radiological 
status  (i.e.  presence  or  absence  of  SCI)
280.  Controls  generally  had  the  largest  mean 
volumes, followed by the SCI- group, then the SCI+ group. These results indicate patients 
with  SCD,  in  which  SCI  is  present  or  absent,  are  at  risk  for  subcortical  grey  matter 
volumetric deficits.   81 
(mm3)  Control (n=69)  SCI- (n=56)  SCI+ (n=28)  ANOVA F  ANOVA p  Post-hoc 
Intracranial Volume  1532863.03  14886260.86  1503160.55 
     
Left Cerebellar Cortex  57533.46  54924.89  53884.29  6.381  0.002** 
a**, d= 0.65 
b*, d= 0.50 
Left Thalamus  7544.74  7419.30  7521.39  0.149  0.866 
 
Left Caudate  3831.94  3771.48  3748.14  0.084  0.917 
 
Left Putamen  5420.70  5447.21  5260.25  0.609  0.546   
Left Pallidum  1713.58  1664.70  1665.36  1.698  0.187 
 
Left Hippocampus  3999.52  3883.80  3751.93  3.016  0.052  a
†, d= 0.54 
Left Amygdala  1479.04  1371.89  1355.89  6.424  0.002 ** 
a*, d= 0.55 
b**, d= 0.52 
Left Accumbens  535.33  561.82  556.61  0.346  0.708 
 
Right Cerebellar Cortex  60028.39  55993.29  55302.32  10.785  4.28 x 10
-5 *** 
a***, d= 0.76 
b***, d= 0.68 
Right Thalamus  7535.17  7439.11  7314.82  0.736  0.481 
 
Right Caudate  3734.45  3674.75  3576.79  0.509  0.602 
 
Right Putamen  5340.78  5305.68  4899.25  5.994  0.003 ** 
a**, d= 0.69 
c*, d= 0.70   82 
Table 5-2. Means and standard deviations of subcortical volumes. 
(mm
3)  Control (n=69)  SCI- (n=56)  SCI+ (n=28)  ANOVA F  ANOVA p  Post-hoc 
Right Pallidum  1586.94  1580.64  1481.07  2.323  0.101 
 
Right Hippocampus  4031.13  3898.38  3850.68  1.473  0.233 
 
Right Amygdala  1572.41  1429.18  1462.00  7.115  0.001 **  b**, d= 0.64 
Right Accumbens  516.29  535.64  533.36  0.205  0.815 
 
 Subcortical Grey Matter Volume  196415.20  187084.64  185281.25  8.473  3.30 x 10
-4 ** 
a**, d= 0.67 
b**, d= 0.61 
 
aPost-hoc: Controls > SCI+, 
bPost-hoc: Controls > SCI-, 
cPost-hoc: SCI- > SCI+  
after correction for multiple comparisons *p<0.05, **p<0.01, ***p<0.001, 
†indicates trend (p<0.1), 
d: Cohen’s d for effect size   83 
 
Figure 5-4. ANCOVA results of significant subcortical volumes.    84 
5.6.2  Correlation with Age 
Pearson’s  r  correlations  were  performed  between  age  and  each  group’s  subcortical 
volumes, using residual data corrected for intracranial volume and gender. Table 5-3 shows 
correlation  results  for  each  group,  and  significance  after  correction  for  multiple 
comparisons.  
In the control group, generally all correlations were negative, indicating decrease in volume 
with  increasing  age.  The  majority  of  correlations  in  the  SCI-  group  were  also  negative, 
except  for  positive  correlations  for  left  thalamus  and  right  hippocampus.  More  positive 
correlations  were  found  in  the  SCI+  group,  in  the  bilateral  cerebellar  cortices,  bilateral 
amygdalae, left accumbens, and total subcortical grey matter volume.  
Both putamena showed significant negative correlations with age, in both the controls (left 
putamen: r= -0.430; right putamen: r= -0.462) and SCI- group (left putamen: r= -0.414; right 
putamen:  r=  -0.487)  with  over  90%  power.  Both  pallida  showed  a  significant  negative 
correlation in the SCI- group (left pallidum: r= -0.476; right pallidum: r= -0.513) with over 
97% power. The right pallidum significantly correlated with age in controls (r= -0.317, with 
76% power) while the left pallidum showed a trend-level correlation (r= -0.273, with 62% 
power). To achieve 80% power in the right and left pallidum, the sample size would need to 
include  76  and  103  control  subjects,  respectively.  In  the  SCI-  group,  both  accumbens 
nuclei  showed  a  significant  negative  correlation  (left  accumbens:  r=  -0.430,  with  92% 
power; right accumbens: r= -0.363, with 79% power). In the control group, only trend-level 
negative correlations were found; for the left accumbens the correlation was r= -0.298 with 
70% power and the right accumbens was r= -0.281 with 44% power. To achieve 80% 
power for the correlation of left and right accumbens with age, the sample size would need 
to  include  86  and  97  control  subjects,  respectively.  The  left  cerebellar  cortex  volume 
significantly negatively correlated with age in the SCI group (r= -0.312, with 65% power), 
but no significant correlations were found in the control or SCI+ groups. To achieve 80% 
power, 79 SCI- patients would have been required for this correlation.  
Figure  5-5  shows  the  residual  data  scatter  plots  for  volumes  that  showed  significant 
correlations with age (bilateral putamena, bilateral pallida, bilateral accumbens nuclei, left 
cerebellar cortex), separated by Control, SCI- and SCI+ groups.   85 
 
Control (n=69)  SCI- (n=56)  SCI+ (n=28) 
  Pearson’s r  p  Power 
n for 80% 
power 
Pearson’s r  p  Power 
n for 80% 
power 
Pearson’s r  p 
Left Cerebellar 
Cortex 
-0.153  0.211      -0.312  0.019*  65%  79  0.249  0.200 
Left Thalamus  -0.222  0.066      0.105  0.443      -0.080  0.685 
Left Caudate  -0.184  0.206      -0.159  0.243      -0.388  0.041 
Left Putamen  -0.430  0.00023**  96%  -  -0.414  0.0015**  90%  -  -0.405  0.032 
Left Pallidum  -0.273  0.023
†  62%  103  -0.476  0.00021**  97%  -  -0.369  0.053 
Left Hippocampus  -0.177  0.146      -0.005  0.968      -0.033  0.867 
Left Amygdala  -0.205  0.092      -0.158  0.246      0.174  0.375 
Left Accumbens  -0.298  0.013
†  70%  86  -0.430  0.00093**  92%  -  0.289  0.136 
Right Cerebellar 
Cortex 
-0.158  0.196      -0.190  0.162      0.270  0.165 
Right Thalamus  -0.141  0.248      -0.116  0.394      -0.012  0.952 
Right Caudate  -0.216  0.075      -0.263  0.051      -0.426  0.024 
Right Putamen  -0.462  0.000064**  98%  -  -0.487  0.00014**  97%  -  -0.248  0.204 
Right Pallidum  -0.317  0.008*  76%  76  -0.513  0.000051***  99%  -  -0.316  0.102 
Right Hippocampus  -0.076  0.534      0.075  0.583      -0.087  0.659 
Right Amygdala  -0.074  0.547      -0.049  0.718      0.376  0.049 
Right Accumbens  -0.281  0.019
†  44%  97  -0.363  0.0059*  79%  57  -0.444  0.018 
Subcortical Grey 
Matter Volume 
-0.179  0.140      -0.222  0.099      0.185  0.346 
 
*p<0.05, **p<0.01, ***p<0.001 (after correction for multiple comparisons) 
†indicates trend (p<0.1) 
Table 5-3. Cross-sectional correlations of subcortical volumes with age.   86 
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Figure 5-5. Cross-sectional correlations with age. There are seven plots to this figure: residual 
data (corrected for intracranial volume and gender) of the left- and right-hemisphere putamen, 
pallidum,  acumbens  and  left  cerebellar  cortex  correlation  plots  with  age.  Significance  is 
indicated by star notation at the top of each graph (***p<0.001, **p<0.01, *p<0.05, 
†p<0.1). 
 
5.6.3  Correlation with IQ 
FSIQ from WASI tests were available for 37 control subjects, 30 SCI- patients and 13 SCI+ 
patients.  Pearson’s  r  correlations  were  performed  between  age  and  each  group’s 
subcortical volumes, using residual data corrected for intracranial volume age, gender and 
the interaction between age and gender. There were no significant correlations between any 
volume and FSIQ in any subject group. 
5.7  Discussion 
This  chapter  specifically  investigated  volumes  of  subcortical  structures  in  patients  with 
SCD, with and without SCI, compared to controls. One previous report found volumetric 
decreases  in  central  grey  matter
200;  however  this  current  study  found  more  specific   90 
significant differences of volumes of the bilateral cerebellar cortices, bilateral amygdalae, 
and right-hemisphere putamen, as well as total subcortical grey matter volume.  
This  study  follows  a  voxel-based  morphometry  analysis
199,  which  found  significant 
decreases in white matter density bilaterally. These authors also reported a trend regarding 
cortical grey matter density; in the lesion group, grey matter density was decreased along 
the medial wall of the frontal and the parietal lobes surrounding the cingulate sulcus, and in 
the patients without lesions, grey matter density reductions were seen in the same, but 
smaller, regions. Our findings are in line with these reports, as the trend for decreasing 
subcortical volumes followed similar ordering of groups by radiological status (i.e. SCI+ < 
SCI- < Controls).  
5.7.1  Comparison with Previously Reported Data 
A  subset  of  these  data  has  been  published  previously  in  the  British  Journal  of 
Haematology
280. This study expanded on that short report with a larger cohort and a wider 
age range. The original study, with 13 SCI- patients, 13 SCI+ patients and 20 controls, 
indicated  significant  group  differences  in  the  bilateral  cerebellar  cortices,  bilateral 
hippocampi,  bilateral  amygdalae,  bilateral  pallida,  right-hemisphere  caudate,  right-
hemisphere putamen and total subcortical grey matter volume. After adding more subjects, 
original group differences remained significant for the bilateral cerebellar cortices, bilateral 
amygdalae, right putamen, and total subcortical grey matter volume; however, results were 
no longer significant in the bilateral hippocampi, bilateral pallida, and right caudate. In the 
original study, group differences in the bilateral hippocampi, left pallidum and right caudate 
were significant just under p<0.05, with the control group having significantly larger mean 
volume than the SCI+ group. In the right pallidum, controls had significantly larger mean 
volume than both SCI- and SCI+ groups (p<0.01). In the current, expanded cohort, these 
results are no longer significant, possibly due to larger sample size and more statistical 
power that nulled. 
Figure 5-6 shows bar graphs from the original study, compared with the analysis from the 
expanded  cohort  for  the  volumes  of  the  structures  that  remain  significant  with  the 
expanded analysis. In the right cerebellar cortex and bilateral amygdalae, the difference 
between controls and SCI- group was found to be more highly significant, and statistical 
significance remained between controls and SCI+ groups. In the right putamen, there was a 
new finding in the current expanded study: SCI- patients had significantly larger volume 
than SCI+ patients (p<0.05), which is the only statistical difference in any volume between 
those two groups. Results for total subcortical grey matter volume remained significant in 
the current study.    91 
There were more statistical differences between Controls and patient groups than between 
the SCI- and SCI+ groups. This provides further evidence to support the hypothesis that 
lesion size alone may not be predictive of brain injury
221, as volumetric deficits are seen in 
patients without visible lesions compared to controls. This is in line with previous studies 
showing cortical grey matter loss
202 in patients with no visible abnormality on T2-weighted 
MRI.  It  is  possible  that  deficits  in  brain  volume  are  a  result  of  SCD-specific  chronic 
physiological processes, such as perfusion abnormalities as well as chronic, intermittent 
anaemia and hypoxia.     92 
 
Figure 5-6. Comparison of results with previously reported data
280, in which sample sizes were 
smaller (i.e. previously reported data: Controls: n=20, SCI-: n=23, SCI+: n=13; current analysis: 
Controls: n=69, SCI-: n=56, SCI+: n=28). Red post-hoc lettering indicates results that became 
significant in current analysis, and grey post-hoc lettering indicates results that are no longer 
significant in current analysis.    93 
5.7.2  Correlation with Age 
The  current  study  showed  significant  negative  correlations  with  age  in  both  the  control 
group and the SCI- group in the bilateral putamena, pallida and accumbens nuclei. While 
correlations  with  age  between  controls  and  the  SCI-  group  were  similar  in  the  bilateral 
putamena, in the bilateral pallida and bilateral accumbens nuclei, the SCI- group showed 
stronger and more statistically significant correlations with age than controls. 
Cross-sectional data from healthy subjects aged 4-18 years, without use of any covariates, 
show a curvilinear (inverted-U curve) shape for subcortical grey matter volume and several 
subcortical  structures  (thalamus,  caudate  nucleus,  putamen  and  globus  pallidus)  and 
cerebellum
290.  This  study  sampled  325  individuals  and  there  was  wide  inter-subject 
variability  and  large  confidence  intervals;  however,  total  subcortical  grey  matter  volume 
displayed an increase in volume until approximately age 11.5 years, then an age-related 
decrease. A significant age-related increase in volume was found for the thalamus, while 
significant age-related decreases were found for the caudate and globus palldius
290. The 
current findings of the volume of the pallidum are in line with that study.  
A longitudinal two-timepoint study of subcortical brain maturation in healthy children aged 
11-17  years  showed  age-related  increases  in  the  hippocampus,  pallidum  and  left 
accumbens,  and  age-related  decreases  in  the  putamen,  caudate,  thalamus  and  right 
accumbens
291. There were no significant positive correlations with age in this current study, 
although the current findings for the accumbens are in line with those results.  
For the bilateral accumbens nuclei, bilateral pallida and left cerebellar cortex, significant 
negative  correlations  with  age  were  stronger  in  the  SCI-  group  than  controls,  although 
formal  statistical  testing  was  not  done  to  determine  differences  in  age  by  group 
interactions.  These  volumes  may  suggest  specific  biomarkers  for  subcortical  volumetric 
deficit as a function of age. However, these data cannot discern between whether children 
with SCD have smaller brain volume at a younger age initially, whether this is an indication 
of atrophy with increasing age or what factors specific to SCD may cause this process. 
Further  research  could  investigate  functions  associated  to  the  nucleus  accumbens  in 
adolescents and adults with SCD. In multiple sclerosis, similar volumetric reductions of the 
nucleus accumbens have been found, potentially due to loss of myelin and/or axons
292,293, 
and smaller nucleus accumbens volume correlated with steeper cognitive decline in older 
people
294.  
There  were  no  significant  correlations  with  age  in  the  SCI+  group.  This  is  in  line  with 
findings of differing patterns of subcortical volumetric growth as reported previously
200, with 
brain  volume  increasing  in  SCD  at  an  age  when  brain  volume  in  controls  had  already 
stabilised. That study did not discern patients with or without visible SCI on T2-weighted   94 
MRI,  so  specific  group  trajectories  are  unknown.  However,  the  authors  suggest  the 
possibility  that  developmental  processes  occur  at  a  slower  rate  in  children  with  SCD 
compared to healthy controls, similar to evidence in SCD for a somatic growth delay
263,295. 
The notion that SCD is a type of neurodevelopmental disorder has also been described in 
the cognitive literature
296. 
5.7.3  Silent Cerebral Infarction and Brain Development 
SCI are clinically silent and it is unknown when neurological abnormalities occur. The lack 
of epidemiological studies to determine the natural history of SCI remains a limitation
105. It 
has been reported that SCI occurs in one-quarter of children under 6 years
183 and one-third 
of children under 14 years
297.  There  are  few  studies  in  very  young  children,  as  children 
generally  do  not  tolerate  MRI  investigation  younger  than  age  6;  however  studies  have 
reported SCI in 4 of 39 children (10%) between 7-48 months of age
107, and 3 of 23 infants 
(13%) with a mean age of 13 months
182. It is unknown whether the first incidence of SCI can 
occur in adolescence, or whether there is an “incidence plateau”
105 during adolescence into 
adulthood.  
This study excluded multiple within-subject scans; taking into account only the most recent 
MRI from 14 subjects that had repeat 3D T1-weighteed MRI. However, a slightly larger 
group  of  patients  from  the  2000-2002  East  London  cohort  and  the  2005-2007  SIT  trial 
cohort with T2-weighted MRI returned for follow-up scans as part of the 2012-2013 London 
cohort. An experienced neuroradiologist read each subjects’ baseline and follow-up T2-
weighted  image  to  determine  any  progression  of  neurological  abnormality  (i.e.  new  or 
enlarged lesions). 
In the 2000-2002 East London cross-sectional study, 10 subjects with T2-weighted MRI (3 
SCI-, 7 SCI+, age range: 7-23 years) had a follow-up MRI scan 10-12 years later. All 3 SCI- 
patients  and  4  SCI+  patients  at  baseline  had  no  reported  change  at  follow-up  MRI. 
However, 3 male SCI+ patients had evidence of new SCI during the interim. Patient 1 was 
17 years old at baseline MRI with evidence of a right frontal white matter lesion – at age 28 
at follow-up MRI there was evidence of a new right-hemisphere peritrigonal lesion. Patient 2 
was 21 years old at baseline MRI with evidence of a left parietal white matter lesion – at age 
33  at  follow-up  MRI  there  was  evidence  of  two  new  frontal  lobe  white  matter  lesions. 
Patient 3 was 7 years old at baseline MRI with left peritrigonal lesions – at age 18 at follow-
up MRI there was evidence of two bilateral cerebellar white matter lesions.  
In the group not randomised to the SIT trial, 7 patients (6 SCI-, 1 SCI+, age range 7-10 
years) had a follow-up scan 4-7 years later. All 7 subjects showed no further abnormality on 
the follow-up scan.   95 
Interestingly, two of the three SCI+ patients that did show progression of abnormal MRI had 
developed new SCI after age 18; however all three patients that showed progression of 
abnormality  had  existing  SCI  at  baseline,  giving  no  information  on  whether  there  is  an 
“incidence plateau” of first SCI in childhood
105.  
5.7.4  Limitations 
This study investigated group differences in subcortical volumes cross-sectionally, in which 
the  large  scatter  of  data  and  large  standard  error  sizes  may  reshape  interpretation  of 
results. Ideally, matched control and patients samples of longitudinal within-subject data 
from a young age would provide information about the long-term rate of growth and/or 
atrophy over childhood, adolescence and into adulthood in people with SCD.  
In this study, the group sizes were different and there were fewer subjects encompassing 
the  middle  and  oldest  of  the  age  range  within  the  SCI-  and  SCI+  groups,  leading  to  a 
significantly older control and SCI+ group than the SCI- group. The sparsity of data that 
cover the entire age range limits the ability to ascertain nonlinear relationships; therefore 
linear functions were used, similar to earlier reports
290,298,299.  
This study also includes data collected over a twelve-year period on three different 1.5T 
MRI  scanners  at  Great  Ormond  Street  Hospital.  Although  the  majority  of  patients  and 
controls were scanned on the newest system, image resolution of the T1-weighted volume 
scan  varied  within  one  millimetre  in  voxel  dimensions,  potentially  skewing  volumetric 
results.  For  each  individual  subject  before  any  volumetric  segmentation  or  labelling, 
Freesurfer  automatically  corrects  for  non-uniformity  in  signal  intensity  and  computes  an 
affine transformation to standard atlas space. These steps acted to standardize all subjects’ 
scans within the sample and reduce variability in volumetric calculation
300.         
5.8  Conclusion 
This study shows that previously described cortical atrophy and white matter abnormalities 
in SCD are accompanied by volumetric loss of tissue in subcortical grey matter structures. 
Although the SCI- group showed significant negative correlations with age comparable to 
the control group, there were no significant correlations in the SCI+ group. These findings 
are consistent with the hypothesis of a global diffuse pattern of brain injury, with complex 
patterns of brain development. Future research should explore longitudinal within-subject 
studies and relationships with cognition and ‘soft’ neurological signs
101 over time.  
     96 
Chapter 6.  Evidence for brain atrophy in paediatric 
SCD: Findings from the Silent Infarct Transfusion (SIT) 
Trial 
Silent  cerebral  infarction  (SCI)  is  caused  by  several  possible  circular  processes:  small 
vessels can be occluded by irreversibly sickled cells, leading to microcirculatory ischaemia 
in  the  arterial  borderzones  where  flow  may  be  relatively  low  compared  with  metabolic 
demand, and abnormally high arterial blood velocities can cause injury to the endothelial 
cells lining the vascular wall, leading to distal stenosis and occlusion
89,90. Presence of SCI is 
a risk factor for additional neurologic injury, including clinical stroke and progression of 
SCI
108,301.  
The profile of lesions occurring in the non-motor areas of the brain, particularly the frontal 
lobes
104,224, has also been associated with marked deficits in cognitive performance. Several 
studies have reported lower IQ scores in patients with SCI compared to those with normal 
MRI
216,218,220,223. Other domains such as executive functioning
115, sustained attention
219,226,227, 
cognitive  flexibility,  working  memory
230  and  processing  speed
217,219,233,253,  have  also  been 
reported to be affected. 
Studies  have  shown  brain  morphological  changes  in  children  with  SCD.  A  voxel-based 
morphometry study showed children with SCI had significant decreases in white matter 
density extending along the ventricles in an arterial borderzone distribution
199, compared to 
those with normal MRI. Cortical thinning has been reported in older children with SCD and 
normal MRI compared to controls
202. Specific volumes of subcortical structures are also 
decreased in children with SCI, with the largest significant decreases in those with SCI, 
followed by those with normal MRI and controls
280.  
Little is known about long-term brain morphometric changes in children with SCD and SCI. 
The  Silent  Infarct  Transfusion  (SIT)  trial  (principal  investigator  Dr  Michael  DeBaun, 
Washington University School of Medicine) provides the unique opportunity to study intra-
subject changes over approximately three years during childhood and adolescence. The 
SIT trial focuses on blood transfusions as therapeutic intervention, based on compelling 
evidence  from  the  previous  STOP  I  (Stroke  Prevention  in  Sickle  Cell  Anemia)  trial,  that 
showed a clear benefit of transfusion in preventing stroke
123. Evidence from the STOP I trial 
also  showed  none  of  the  18  patients  with  baseline  silent  infarcts  who  were  receiving 
transfusions developed new MRI lesions over a 36-month follow-up period, whereas of 29 
untreated  children  with  baseline  silent  infarction,  52%  developed  new  MRI  lesions  or 
suffered  overt  strokes
109.  The  primary  hypothesis  of  the  SIT  trial  was  that  transfusion 
therapy  would  result  in  at  least  86%  reduction  in  new  overt  and  silent  strokes.  Also,   97 
secondary hypotheses put forward were that transfusion therapy will limit further decline in 
general intellectual abilities when compared to the observation arm and that the overall 
benefit of transfusion therapy will outweigh the risks associated with the treatment.   
The present study examines brain volume change over 3 years in children that participated 
in the SIT trial to determine the impact of blood transfusion therapy on brain volume. The 
study  employed  structural  image  evaluation  of  T1-weighted  anatomical  MRI  data  using 
normalisation  of  atrophy  (SIENA)
302,  a  semi-automated  quantification  of  two-timepoint 
whole-brain  percent  brain  volume  change.  SIENA  is  a  reliable  measure  of  estimating 
longitudinal changes in global brain volume
302 and has been utilised in disorders such as 
multiple sclerosis
303 and small vessel disease
304,305, as well as traumatic brain injury
306,307 and 
normal aging populations
308,309. To date, there are no studies investigating longitudinal brain 
volume change in children with SCD. In line with the hypotheses of the SIT trial, the primary 
hypothesis of this exploratory study is that transfusion therapy will have a protective effect 
on any brain volume loss that may occur due to progression of cerebrovascular disease.  
6.1  Methods 
1.1.1  Design of the SIT Trial 
In this multicentre study, 29 clinical centres participated; 1211 children between the ages of 
5  and  15  were  screened  and  196  patients  randomised  to  either  blood  transfusion  or 
observation.  Details  of  the  inclusion  and  randomisation  criteria  have  previously  been 
published
160,186. Design of the SIT trial is shown in Figure 6-1.  
Participants  who  were  randomised  to  observation  received  standard  care,  while  those 
randomly assigned to transfusion received a transfusion approximately monthly to maintain 
haemoglobin concentration greater than 9 g/dL and haemoglobin S concentration less than 
30%
160. 
The definition of SCI, as determined by the SIT trial investigators, is an increase in signal 
intensity seen on T2-weighted MR images, with no history of neurological deficit lasting 
more than 24 hours. For the SIT trial, the MRI lesion must measure at least 3mm in greatest 
linear dimension, visible in at least 2 planes of fluid-attenuated inversion recovery (FLAIR) 
T2-weighted  images  (axial  and  coronal)
111,186.  Two  neuroradiologists  had  to  agree  that 
lesions were present and could not be explained by abnormality on neurological exam.   98 
 
 
 
Figure 6-1. Design of the SIT trial.   99 
6.1.1  Participants 
Inclusion criteria for the present study included: randomisation to the SIT trial (i.e. patients 
with evidence of SCI at baseline), and MRI investigation at pre-randomisation and trial exit. 
MRI at both time points had to be on a 1.5T scanner, and must have included a 3D T1-
weighted sequence for volumetric analysis. 
6.1.2  Scanner Variability 
Study participants from 5 US and 2 UK sites were included in this study. At 6 sites, 23 
patients were scanned on the same system on both pre-randomisation and exit MRI. At 4 
sites, 9 patients’ exit MRI investigation was performed on a different scanner from pre-
randomisation MRI. Refer to Figure 6-2 for details of MRI sequences.  
Analysis included a binary factor to explain variability in whether the same or a different 
scanner was used. Patients were coded as having the same scanner system if the scanner 
underwent a software upgrade in the interim (n=6 patients at 3 sites).  
6.1.3  SIENA %BVC analysis 
SIENA
302  (FSL
242;  http://www.fmrib.ox.ac.uk/)  was  used  to  estimate  percentage  brain 
volume change (%BVC). SIENA goes through four steps to calculate %BVC between two 
time points: 
1.  Whole  head  data  is  used  to  extract  brain  and  skull  images.  Automatic  brain 
extraction masks were manually checked to ensure adequate brain extraction and 
exclusion of non-brain tissue
310.  
2.  The two brain-masked images are aligned to each other and sampled to a halfway 
space.  
3.  Tissue type segmentation is carried out to find brain/non-brain edge points, and  
4.  Perpendicular edge displacement between the two time-points is estimated. The 
mean edge displacement is calculated as the global estimate of %BVC. A negative 
%BVC indicates ‘atrophy’, while a positive %BVC indicates ‘growth’ (Figure 6-3).  
SIENA  %BVC  was  calculated  for  each  patient  for  the  time  lapse  between  the  pre-
randomisation and exit MRI scans, then calculated as a %BVC/year index to control for 
varying time lapses between scans. 
     100 
 
Figure 6-2. Details of MRI sequences across 7 sites of the SIT trial.   101 
 
 
Figure 6-3. SIENA analysis pipeline.   102 
6.1.4  Cognitive Data 
Neuropsychological data were acquired at baseline (around the time of pre-randomisation 
MRI) and study exit. A measure of Full-Scale IQ (FSIQ) was collected from the 4-subtest 
Wechsler Abbreviated Scale of Intelligence (WASI). Change in FSIQ per year was calculated 
by the difference in FSIQ scores divided by the time lapse between cognitive testing. 
6.1.5  Statistical Analysis 
Statistical  analyses  were  computed  with  R  (http://www.r-project.org/).  The  intent  for 
statistical  analysis  was  to  investigate  differences  between  treatment  groups  while 
controlling for factors known to influence brain structure and volume.  
A  model  was  fitted  to  the  data  to  examine  the  influence  of  treatment  group,  while 
controlling  for  any  effect  of  age,  gender,  scanner  variability,  and  also  the  interactions 
between  treatment  group,  age,  gender  and  scanner  variability.  A  Pearson’s  product 
moment correlation (r) was carried out to correlate age-, gender-, and scanner-corrected 
residual data of %BVC/year and FSIQ.  
6.2  Results 
Forty-one participants met the inclusion criteria. Due to poor quality data, 9 patients were 
excluded  from  analysis,  leaving  32  patients  (16  on  observation,  16  on  transfusion). 
Demographics and results for the SIENA cohort are displayed in Table 6-1. There was a 
significant difference in gender distribution between the two groups (χ
2= 4.571, p=0.037), 
but no significant difference in age. There were no significant differences in baseline or exit 
FSIQ, although effect sizes were 0.53 and 0.65, respectively. The mean time lapse between 
pre-randomisation MRI and exit MRI in both groups was 3.2 years, range 2.8-3.5 years.  
6.2.1  Effect of Treatment  
After applying the model that took into account age, gender and variability in scanner, there 
was no difference in %BVC/year between the two groups (observation: mean= -0.62%, 
sd=0.44%; transfusion: mean= -0.96%, sd=1.00%; ANOVA F=0.0013, p=0.972). The effect 
size of the difference in means was calculated as -0.44, and the ANOVA F test had 67% 
statistical power. For the same effect size with 80% statistical power, there would needed 
to include 22 patients per group.   103 
6.2.2  Effect of Age 
There was a significant influence of age at pre-randomisation to the trial on %BVC/year 
(ANOVA F=8.842, p=0.007). There was also a trend for a group by age interaction (ANOVA 
F=4.157, p=0.054). In the observation group, correlation with age was non-significant (r= 
0.193, p=0.473), but in the transfusion group, correlation between %BVC/year with age was 
significant (r= -0.663, p=0.003), indicating older children who underwent transfusions had 
greater %BVC/year than those on observation (Figure 6-4). 
6.2.3  Correlation with FSIQ  
Baseline and exit FSIQ assessments were available for 29 patients (15 on observation, 14 
on  transfusion).  There  were  no  significant  differences  in  mean  FSIQ/year  change 
(observation: mean=-0.61, sd=2.38; transfusion: mean=-0.12, sd=3.55; t= 0.179, p=0.666). 
Residual data of SIENA %BVC/year (corrected for age, gender, and variability in scanner) 
did not correlate significantly with FSIQ/year change (r=0.068, p=0.725). 
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Sample n  32 
 
 
Genotype 
27 HbSS 
2 HbS B
0-thalassaemia 
3 unknown   
 
By Treatment Group  Observation (n=16)  Transfusion (n=16) 
 
 
Gender  6M, 10F  12M, 4F  χ
2= 4.571, p=0.037   
Age at Pre-randomisation MRI 
(years; mean ± sd) 
9.41 ± 2.54  11.06 ± 2.12  t= -1.99, p=0.055 
 
Cognitive Data
a  Observation (n=16)  Transfusion (n=16) 
 
Effect size (Cohen’s d) 
Baseline FSIQ (mean ± sd)  95.87 ± 7.78  88.71 ± 13.56  t=1.725, p=0.096  0.65 
Exit FSIQ (mean ± sd)  94.33 ± 10.30  88.07 ± 13.34  t= 1.428, p=0.164  0.53 
FSIQ/year (mean ± sd)  -0.61 ± 2.38  -0.12 ± 3.55  t=0.179, p=0.666  0.16 
MRI Analysis  Observation (n=16)  Transfusion (n=16) 
 
 
Time lapse (years) 
mean= 3.20 ± 0.22 
range: 2.84-3.84 
mean= 3.11 ± 0.13 
range: 2.93-3.47   
 
SIENA % Brain Volume 
Change
† 
mean= -0.62 ± 0.44% 
range: -1.80 - 0.24 
mean= -0.96 ± 1.00% 
range: -2.91 ± 0.319 
ANOVA F= 0.0012, 
p=0.972  0.44 
aavailable for 29 of 32 subjects who had baseline and exit FSIQ available. 
†calculated per year (i.e. volume change/time lapse).
 
Table 6-1. Demographics and results of SIENA analysis.   105 
 
Figure 6-4. SIENA %BVC/year between observation and transfusion groups. Left: Boxplot indicating differences in variation of %BVC/year between groups. 
Right: Scatter plot with age at pre-randomisation between groups.   106 
6.3  Discussion 
This  is  the  first  study  to  date  to  investigate  within-subject  longitudinal  change  in  brain 
volume in children and adolescents with SCD. This study aimed to characterise rates of 
annual growth or atrophy in a subset of children with SCD with existing SCI who were 
randomised to the SIT trial. Our primary hypothesis was not supported; over approximately 
a  three-year  period,  there  were  no  significant  differences  in  brain  volumetric  change 
between the observation and transfusion arms of the trial. Further, the results do show a 
significant group by age interaction, driven by the transfusion group. This suggests that 
older children who underwent transfusions had greater brain volume loss than those who 
were on observation.  These results suggest that transfusion treatment has a differential 
effect on %BVC/year with age. 
6.3.1  %BVC/year compared with other populations 
In a healthy population between the ages of 4 and 18 years, total brain volume was shown 
to follow an inverted U-shaped curve, increasing until about age twelve, then decreasing by 
quadratic age of 0.09%
290. The observed rate of atrophy in the patients in this study was 
0.62% for those on no treatment and 0.96% for those on transfusion therapy. There was a 
significant difference in gender proportion between the two patient groups, but after this 
factor was taken into account, along with age at pre-randomisation and scanner variability, 
showed no statistical differences between the two groups. 
The  rates  of  atrophy  from  this  study  are  greater  than  the  reported  0.15%  error  in 
reproducibility experiments in healthy adult subjects
302, and greater than previous reports in 
healthy aging populations. In volunteers aged 50-75 years, %BVC/year was -0.4%
308, and 
in volunteers aged 38-82 years, it was -0.23% ± 0.36%
309. Two studies have investigated 
brain atrophy in adults with cerebral small vessel disease, finding values of %BVC/year of -
0.56% ± 0.74%
304 and -0.914% ±0.16%
305. The values in middle-aged and elderly patients 
with small vessel disease and cerebral autosomal-dominant arteriopathy with subcortical 
infarcts and leukoencephalopathy (CADASIL) are in line with our results. Although the SIT 
trial showed reduction of recurrence of cerebral infarct in the transfusion arm
160, there is no 
evidence from our study for a protective effect on progressive cerebral atrophy, perhaps 
because the mechanisms causing recurrent infarction and progressive atrophy are different.    107 
6.3.2  %BVC/year compared with other SCD longitudinal data 
Six adolescents with no evidence of baseline SCI and therefore not randomised to the SIT 
trial returned for follow-up MRI between 3.6 and 7.9 years later. All six had baseline and 
follow-up MRI on the same scanner system (at Site 7: see Table 6-1 for sequence details). 
On follow-up MRI, all six were declared to still have no evidence of SCI and none were on 
regular transfusion treatment. For these six patients (mean age at first scan: 8.53 years, 
range: 8.08 - 10.23 years, 3 males), mean %BVC/year was -0.58% (range: -1.28 – 0.24%).  
Due to small sample sizes, formal statistical testing was not performed, although effect 
sizes were calculated between groups. The difference between the SIT observation group 
(n=16, mean %BVC/year: -0.62%) and the no-SCI group was 0.04% (effect size: -0.08). The 
difference between the SIT transfusion group (n=16, mean %BVC/year = -0.96%) and the 
no-SCI group was 0.38% (effect size: -0.41; Figure 6-5).  
 
Figure 6-5. Comparison with longitudinal non-radomised SIT patient data. 
 
Additionally, one male sibling control subject originally scanned in 2002 as part of the East 
London cohort returned in 2013 for a follow-up MRI. Age at first scan was 18.34 years, and 
the %BVC/year calculated between the two time points was -0.47% (not pictured in Figure   108 
6-5).  This  rate  of  change  falls  within  range  of  similar  healthy,  but  slightly  older, 
populations
308,309. 
The inclusion of a ‘control’ group with no evidence of SCI on MRI allows for some further 
interpretation of the SIT trial reported atrophy results. Although statistical testing between 
the  two  SIT  groups  and  the  no  SCI  group  was  not  performed,  there  are  no  obvious 
differences in the mean %BVC or range of %BVC between the two untreated groups (i.e. 
SIT observation group and the no SCI group),  suggesting  that  rates  of  atrophy  are  not 
solely due to presence of existing cerebrovascular disease. These preliminary findings give 
some indication that atrophy may be a result of subtler effects of chronic disease on the 
brain, rather than exclusively presence of SCI.  
6.3.3  Limitations 
This study is limited by unavailability of clinical data from this trial. During the analysis of 
this work, main trial findings had yet to be published and medical data was therefore not 
shared.  Clinical  information  regarding  disease  severity  (i.e.  markers of anaemia such as 
haemoglobin,  haematocrit  and  oxygen  saturation)  may  have  mediating  effects  on  these 
reported results.  
In a multicentre longitudinal study over years, it is difficult to guarantee that clinical scanner 
systems will stay the same for all acquired scans for the duration of the study. Change in 
intensity  of  tissues  from  different  scanner  systems  may  introduce  systematic  error  for 
automatic segmentation software. SIENA segments the brain and estimates the outer skull 
surface  for  both  pre-randomisation  and  exit  time  points  and  uses  12-parameter  affine 
transformation (translation, rotation, scaling and skew) to register the two images
302. Then, 
brain edge points in both images are compared, and SIENA estimates motion of each brain 
edge point from one time point to the next. One study investigating intra-scanner variability 
error noted SIENA mean edge displacement algorithm is relatively insensitive to changes in 
intensity  of  tissues  from  one  scan  to  the  next
311.  A  reproducibility  study  to  explain  the 
variance in longitudinal volumetric data in children is therefore warranted. 
6.4  Conclusion 
This chapter showed evidence of longitudinal brain atrophy in children with SCD who were 
randomised  in  the  SIT  trial.  Although  the  main  trial  results  showed  transfusion  therapy 
reduced risk of new or progressive SCI, the results from this study show no protective 
effect of transfusion therapy on rate of brain atrophy.    109 
Chapter 7.  White matter abnormalities relate to oxygen 
saturation in asymptomatic children with sickle cell 
anaemia 
Up to 35% of patients who have silent cerebral infarcts (SCI)
78,110, with MRI lesions typically 
present in the deep white matter of the centrum semiovale in arterial borderzone regions, 
usually  between  the  anterior  and  middle  cerebral  arterial  territories
312.  SCI  are  common 
within  the  first  decade  of  life,  and  can  have  devastating  effects  on  cognitive  abilities, 
including  intelligence
104,218  and  executive  functioning
115,248.  Children  with  SCA  with  no 
evidence  of  infarction  or  abnormalities  on  conventional  T2-weighted  MRI  still  show 
reduction  in  cognitive  function  compared  to  healthy  age-  and  race-matched 
controls
106,114,220; therefore one can assume there may be abnormalities in the brain beyond 
the detection of conventional MRI methods
200  and that the presence of discrete lesions 
alone may not describe total brain injury.  
The mechanisms for white matter injury in SCA are unclear. Cerebral haemodynamics are 
often abnormal; there is high global cerebral blood flow but regional reductions, increasing 
the  risk  of  ischaemia  in  the  territories  of  stenosed  large  vessels  and  the  borderzones 
between them
92,93,259. The risk of tissue injury is also increased by chronic anaemia 
79 and 
low oxygen saturation
313, leading to further sickling of the red blood cells
314, increased white 
cell,  platelet,  and  endothelial  activation  and  adherence  of  sickled  cells  to  the  vascular 
endothelium
315.  Low  daytime  and  nocturnal  peripheral  oxygen  saturation has  previously 
been linked to risk of overt stroke
94,313, lower IQ
252 and poorer performance on executive 
function tasks
162 in SCA. Lower IQ and worse executive function, as well as neuronal injury 
in  the  hippocampus,  have  been  reported  in  children  with  sleep-disordered 
breathing/obstructive sleep apnoea in the general population experiencing similar nocturnal 
oxygen  desaturation
316–318.  The  disruption  to  breathing,  which  results  in  reduced  oxygen 
saturation, has been shown to interfere with synaptic plasticity and consequently various 
cognitive functions
319. However in children with SCA, there are no data on any direct link 
between brain structure, oxygen saturation and haemoglobin. 
Diffusion tensor imaging (DTI) provides information about white matter microstructure. The 
technique  known  as  tract-based  spatial  statistics  (TBSS)
242  is  a  whole-brain  voxel-wise 
analysis  without  the  need  for  prior  determination  of  tracts  of  interest.  It  registers  white 
matter, rather than the whole brain, between subjects, resulting in improved registration, 
reduced partial volume effects and no smoothing limitations. There are few diffusion data in 
SCA. TBSS was used
205 to compare two groups of children with SCA, some of whom had 
mild gliosis although none had SCI. Increases in diffusivity and anisotropy reduction in the   110 
body  of  the  corpus  callosum  (CC)  was  found  only  in  patients  with  mild  gliosis,  while 
anisotropy reduction in the centrum semiovale was found in the no-SCI group; however, 
results were not significant at the 95% confidence level. 
A recent study compared sixteen SCA patients (age range of 11-45 years) and a matched 
control  group  in  a  combined  quantitative  DTI  and  deterministic  tractography  analysis
206. 
This study used various regions-of-interests (ROI) across the brain, finding reduced FA in 
the  CC,  centrum  semiovale,  periventricular  areas  and  subcortical  white  matter  ROIs. 
Deterministic  tractography  of  the  CC  was  also  used,  showing  reduced  fibre  count  (i.e. 
streamlines) and reduced FA in the anterior body of the CC. However, these results are 
limited  because  a  significant  proportion  of  the  patient  group  (6  of  16  patients)  had  SCI 
present, potentially augmenting the results. In addition, the effect of a wide age range on 
diffusion data was not controlled for, and there was no correction for multiple comparisons 
after which the findings might not be statistically significant. These studies did not include 
relationships between white matter and any physiological measures. 
The objective of this study was to investigate differences in white matter structural integrity 
in  children  with  SCA  and  controls.  This  study  only  compared  those  with  SCA  and  no 
evidence of abnormalities on T2-weighted MRI to elucidate differences in only the normal-
appearing white matter. We hypothesized firstly that there is structural damage, detectable 
by using a whole-brain voxel-wise white matter analysis, and secondly that the degree of 
damage is related to reduced daytime oxygen saturation and steady-state haemoglobin. 
7.1  Methods 
7.1.1  Participants 
Child and adolescent participants were recruited as part of the 2012-2013 London cohort 
(described in Chapter 3). Inclusion criteria consisted of: participant age between 8 and 18 
years, and having both T2-weighted and DTI sequences. 
7.1.2  Physiological Measures 
From  the  medical  records,  peripheral  oxygen  saturation  measurements  were  collected 
within 3 years of the date of the MRI scan at regular clinic visits when the patient was 
generally well, including a measurement taken on the day of MRI over a 5-minute period 
from a pulse oximeter (Masimo Pronto-7 Pulse CO-Oximeter). Patients had between 3 and 
9 measurements (median 4), and the average oxygen saturation was calculated and used in 
subsequent analyses.    111 
Steady-state haemoglobin was also recorded from the closest available full blood count to 
MRI date from patient’s medical records. 
7.1.3  Neuropsychological Variables 
A measure of full-scale IQ (FSIQ) was obtained using the WASI. For measures of executive 
function, five tests were acquired from the D-KEFS test battery: Tower test (Tower) which 
measures strategic planning and rule learning, Trailmaking Test Visual Scanning condition 
(Scanning) which measures visuomotor processing speed and attention, Trailmaking Test 
number-letter  switching  condition  (Switching)  which  measures  cognitive  flexibility  (i.e. 
multitasking and simultaneous processing), Verbal Fluency letter condition which measures 
systematic retrieval of lexical items, and Colour-Word Interference which measures verbal 
inhibition and cognitive flexibility. The BRIEF parent form was obtained for children younger 
than 16, yielding a global executive composite that represents the child’s overall function. 
Details of neuropsychological tests are reviewed in Chapter 3. Demographics are reported 
in Table 7-1.  
7.1.4  MRI Acquisition 
Details of the MRI protocol are reviewed in Chapter 3.  
7.1.5  DTI Preprocessing 
All scans were visually inspected for abnormalities due to motion, or other artifacts. The DTI 
data were preprocessed using TractoR version 2.3
320 and FMRIB Software Library (FSL) 
version 5.0
242.  Within  each  subject,  a  reference  b=0  volume  was  brain  extracted
321,  and 
diffusion-weighted  volumes  were  registered  to  this  volume  to  correct  for  eddy  current 
distortions. A diffusion tensor was derived at each voxel using a standard least-squares 
process to provide a voxel-wise calculation of FA, MD, AD and RD. 
7.1.6  TBSS Whole-Brain Analysis 
Voxel-wise statistical analysis of FA data was carried out using tract-based spatial statistics 
(TBSS).  Each  subject’s  FA  image  was  aligned  to  every  other  one  and  the  ‘most 
representative’ image was identified as the target image, which was then affine-aligned to 
MNI  standard  space.  All  subjects’  FA  data  were  transformed  to  standard  space  by 
combining nonlinear registration to the representative target FA image and affine transform 
to standard space. A mean FA skeleton (threshold at FA=0.2) was created by restricting to   112 
voxels with the highest FA at the centre of the major WM tracts. Each participant’s FA data 
were projected onto the mean skeleton to allow for voxel-wise cross-subject statistics. In a 
similar manner, MD, AD and RD data were projected onto the skeleton, and these data 
were used for voxel-wise permutation-based analysis. Age and gender were included as 
covariates in the TBSS analyses, which included structural comparisons between patient 
and control groups, and correlations with oxygen saturation and haemoglobin in the patient 
group only. Results were corrected for multiple comparisons using threshold-free cluster 
enhancement (TFCE). 
7.2  Results 
Forty-three patients with homozygous SCA (HbSS) and eighteen controls, including twelve 
siblings, were initially scanned. Thirty SCA patients had no abnormality on T2-weighted 
MRI, while twelve SCA patients were excluded due to presence of SCI. Ten subjects (six 
patients  and  four  controls)  were  excluded  because  of  poor  quality  DTI  data  (i.e.  dental 
brace artefact, head motion, systematic vibration artifact
322). The final dataset used for DTI 
analysis included twenty-five children and adolescents with SCA without SCI and fourteen 
age- and race-matched controls. Figure 7-1 shows a graphical representation of excluded 
subjects and Table 7-1 describes demographics of the final dataset in which DTI data were 
analysed.  
In the patient group, two children were undergoing regular transfusion treatment (abnormal 
transcranial  Doppler  ultrasound,  top-up  for  painful  crises),  two  additional  children  had 
transfusions within three months prior to scan, three children were on hydroxycarbamide 
treatment and seventeen children were receiving no treatment.  
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Figure 7-1. Flowchart detailing the process of subject exclusion from analysis. 
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  SCA (n=25)  Control (n=14)   
Effect 
size 
(Cohen’s 
d) 
HbS genotype  25 HbSS  8 HbAS, 6 
HbAA 
   
Age (mean, sd)  13.07 (2.82)  13.71 (2.93)  t=0.679, 
†p=0.501   
Gender  13M, 12F  7M, 7F  χ2=0.014, p=0.905   
FSIQ (mean, sd) 
103.12 
(11.95) 
108.29 (11.69)  t=1.305, 
†p=0.200  0.436 
Tower (mean, sd)a  9.25 (2.71)  9.86 (2.11)  t=0.720, 
†p=0.476  0.240 
Scanning (mean, sd)  9.60 (3.63)  10.00 (2.88)  t=0.354, 
†p=0.725  0.118 
Switching (mean, sd)a  8.29 (3.37)  7.93 (3.45)  t=-0.318, 
†p=0.753  0.106 
Verbal Fluency (mean, 
sd)a 
10.29 (2.71)  10.43 (2.90)  t=0.146, 
†p=0.884  0.048 
Colour-Word 
Interference (mean, 
sd) 
8.76 (3.22)  8.79 (3.07)  t=0.024, 
†p=0.981  0.008 
BRIEF Global 
Executive Composite 
(mean, sd)
b 
52.18 (10.03)  51.17 (10.73)  t=-0.275, 
†p=0.785  0.092 
Oxygen saturation
c 
mean: 
96.70% 
range: 91-
100% 
mean: 99% 
range: 99-99% 
 
 
 
Haemoglobin
d 
mean: 8.29 
g/dl 
range: 6.40-
12.20 
-     
FSIQ= WASI 2-subtest Full-Scale Intelligence Quotient 
Tower= Delis-Kaplan Executive Function System (D-KEFS) Tower test 
Scanning= D-KEFS Trailmaking Test – Visual Scanning condition 
Switching = D-KEFS Trailmaking Test – Switching condition 
Verbal Fluency = D-KEFS Verbal Fluency – Letter condition 
Colour-Word  Interference=  D-KEFS  Colour  Word  Interference  –  Inhibition/Switching 
condition 
BRIEF = Behaviour Rating Inventory of Executive Function (parent form). 
†Student’s t test. 
aScores available for 24 of 25 SCA subjects. 
bScores available for 12 controls and 22 patients. 
cOxygen saturation available for all SCA subjects and 5 of 14 controls. 
dHaemoglobin available in all SCA subjects. 
Table 7-1. Demographics, physiological and behavioural scores for DTI analysis.  
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7.2.1   Physiological Measures 
Oxygen saturation was available for all patients and five controls, and haemoglobin was 
available for twenty-two patients; patients had lower haemoglobin oxygen saturation and 
haemoglobin than published norms of healthy non-SCA children
323 (Table 7-1). 
7.2.2  Neuropsychological variables 
There were no significant differences between the patient and control groups regarding 
age,  gender,  IQ  or  any  executive  function  measures  (Table  7-1).  Mean  IQ  and  D-KEFS 
scores (except Switching) were lower in patients, and BRIEF scores were higher in patients, 
but these differences were not statistically significant and had small effect sizes (Table 7-1, 
Figure 7-2).  
In the control group, eight had sickle cell trait (HbAS) and six had normal haemoglobin 
genotype (HbAA). Between HbAS and HbAA, there was no significant difference in:  
•  mean IQ score (HbAS=109.6, HbAA=106.5, t=-0.480, p=0.640),  
•  mean Scanning score (HbAS=9.8, HbAA=10.3, t=0.413, p=0.690),  
•  mean Switching score (HbAS=7.9, HbAA=8.0, t=0.064, p=0.952),  
•  mean verbal fluency score (HbAS=10.75, HbAA=10.00, t=-0.464, p=0.651), and  
•  mean colour-word interference score (HbAS=8.38, HbAA=9.33, t=0.563, p=0.584). 
Children  with  HbAS  had  significantly  better  Tower  scores  than  HbAA  (HbAS=11.1, 
HbAA=8.2,  t=-3.605,  p=0.004).  Between  7  HbAS  and  5  HbAA  subjects,  there  were  no 
differences  in  BRIEF  global  executive  composite  score  (HbAS=48.71,  HbAA=54.60, 
t=0.931, p=0.374).  
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Figure 7-2. Results of neuropsychological testing. Patients scored lower on WASI full-scale IQ 
(top left) and higher on BRIEF global executive composite (top right), but differences were not 
statistically significant. On the D-KEFS  measures, patients scored lower on all tests except 
Switching; differences were not statistically significant. 
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7.2.3  Structural TBSS results between patients and controls 
Results of the TBSS analysis comparing patients and controls are shown in Figure 7-3. 
After controlling for the effects of age and gender, FA was significantly lower in patients 
than controls (p<0.05) in the cerebral peduncles and cerebellum. Widespread increases in 
MD  were  found.  Across  frontal  and  parietal  lobes,  genu  of  the  CC,  and  subcortical 
structures and cerebellum, patients had significantly higher MD than controls (p<0.05). RD 
was  significantly  higher  in  patients  than  controls  in  the  frontal  and  parietal  lobes,  and 
bilaterally  in  the  internal  capsule,  anterior  thalamic  radiations,  corticospinal  tract  and 
cerebellum (p<0.05). No significant structural differences were found between patients and 
controls for AD. 
7.2.4  TBSS correlation with oxygen saturation and haemoglobin 
Results  of  the  TBSS  analysis  testing  correlations  between  DTI  parameters  and  oxygen 
saturation and haemoglobin are shown in Figure 7-4. In the patient group, a significant 
negative correlation was found between RD and daytime oxygen saturation in a cluster in 
the genu of the CC (p<0.05; TFCE-corrected). Mean raw values of RD from the ROI that 
significantly  negatively  correlated  with  SpO2  were  extracted  and  a  highly  significant 
correlation was found (r= -0.650, p=0.0004) with 96% statistical power (Figure 7-4, top right 
panel).  
A trend-level negative correlation was found between RD and haemoglobin in the midbody 
and posterior parts of the CC (p<0.1; TFCE-corrected). Mean raw values of RD from the 
ROI  that  significantly  negatively  correlated  with  haemoglobin  were  extracted  and  a 
significant correlation was found (r= -0.456, p=0.022) with 75% statistical power (Figure 7-
4,  bottom  right  panel).  To  achieve  80%  statistical  power,  36  patients  would  have  been 
required.    118 
Figure  7-3.  Whole-brain 
TBSS results. Top panel: FA 
–  purple  voxels  indicate 
areas in which SCA patients 
had  significantly  lower  FA 
than controls. Middle panel: 
MD  –  blue  voxels  indicate 
areas in which SCA patients 
had  significantly  higher  MD 
than controls. Bottom panel: 
RD  –  red  voxels  indicate 
areas in which SCA patients 
had  significantly  higher  RD 
than  controls.  All  results 
significant  at  p<0.05  (TFCE 
corrected)  and  overlaid  on 
the  group  white  matter 
skeleton  (green)  and  the 
study-specific  mean  FA 
template.      119 
Figure  7-4.  TBSS 
correlations  with  daytime 
oxygen  saturation  and 
steady-state haemoglobin in 
patients  only.  Top  panel: 
Blue voxels indicate areas in 
which  RD  significantly 
negatively  correlated  with 
daytime  peripheral  oxygen 
saturation  (p<0.05).  Bottom 
panel:  Red  voxels  indicate 
areas in which RD negatively 
correlated with haemoglobin 
(p<0.1).  All  results  TFCE 
corrected  and  overlaid  on 
the  group  white  matter 
skeleton  (green)  and  the 
study-specific  mean  FA 
template. RD data shown in 
plots are mean values from 
the region-of-interest shown 
on the mean FA template.    120 
7.3  Discussion 
This  is  the  first  diffusion  MRI  study  in  children  with  SCA  with  no  evidence  of  MRI 
abnormalities to link brain microstructure with physiological markers of disease severity. 
Specifically, oxygen saturation was found to correlate significantly with RD in the anterior 
CC and there was a trend-level correlation between steady state haemoglobin and RD in 
the midbody of the CC, suggesting a relationship between chronic oxygen desaturation and 
anaemia  and  white  matter  microstructural  integrity  in  this  population  of  asymptomatic 
children  with  SCA.  This  study  also  confirmed  the  presence  of  widespread  white  matter 
abnormalities. FA was found to be significantly lower in patients, mainly in cerebellar white 
matter, and MD and RD significantly higher in patients in widespread regions in the centrum 
semiovale and subcortical and cerebellar white matter.  
The  sample  of  children  with  SCA  with  no  SCI  showed  no  differences  compared  to  the 
control  group  in  terms  of  IQ  and  six  measures  of  executive  function:  tests  of  visual 
processing speed, planning and cognitive flexibility and verbal fluency, as well as a parent 
questionnaire. We can conclude that differences in microstructural white matter were not 
due to underlying differences in cognitive ability in these domains.  
This study builds upon and extends a previous TBSS study in which three groups (SCA-
mild  gliosis,  SCA-no  lesions  and  controls)  were  compared
205  and  there  were  anisotropy 
reductions and increases in diffusivity in the CC and centrum semiovale, with the greatest 
effects  seen  in  the  mild  gliosis  group,  followed  by  the  no  lesion  group,  compared  to 
controls
205; however, all results were only approaching statistical significance. Our study 
found more widespread and statistically significant differences between SCA patients with 
no SCI compared to controls in FA and diffusivity measures.  
There were statistically significant differences in RD, but not AD. AD is thought to reflect 
structural coherence and alignment of axons in white matter, while RD is thought to reflect 
axon density and membrane permeability
324. Reduced myelination can be represented by 
elevated RD, without a change in AD
175, despite the fact that RD is approximately 30% of 
the  magnitude  of  AD
325.  This  is  consistent  with  results  from  previous  paediatric  TBSS 
studies
326–328.  
7.3.1  Link with oxygen saturation and haemoglobin 
There is an established link between oxygen desaturation and poor cognitive function
252 as 
well as risk of stroke
79, but it is still unclear whether this involves a relationship between 
chronic oxygen desaturation and/or chronic anaemia and white matter damage in children   121 
with  no  SCI.  Acute  silent  cerebral  ischaemic  events,  that  may  or  may  not  develop  into 
visible SCI, occur relatively frequently
112, particularly in relation to acute anaemia
42. Our data 
confirms  that  oxygen  desaturation  also  renders  the  brain  at  continual  risk  for  hypoxic-
ischaemic  injury
329.  In  diffusion  data,  high  RD  could  be  due  to  myelin  loss  and  axonal 
damage, and is likely to be related to the cycle of hypoxia, endothelial inflammation, and 
tissue injury in children with SCA without SCI.  
In the present study, there was a significant negative correlation between oxygen saturation 
and RD in the anterior CC and a negative trend-level correlation between haemoglobin and 
RD in the midbody of the CC using the whole-brain TBSS analysis. Correlations of mean 
raw  RD  values  of  the  ROI  and  oxygen  saturation  and  haemoglobin  had  96%  and  75% 
statistical  power,  respectively.  Although  oxygen  saturation  and  haemoglobin  are 
correlated
330,  one  study  found  that  only  a  small  proportion  of  variance  in  steady-state 
oxygen  desaturation  was  explained  by  chronic  anaemia
95.  It  is  likely  that  oxygen 
desaturation has a more vital role than haemoglobin in white matter viability of frontal lobe 
white matter. 
7.3.2  Neuropsychology 
The results from this sample indicate no significant differences in IQ between children with 
SCA without SCI compared to controls. Previous reports from the CSSCD
106,220 have shown 
that children with normal MRI findings have deficits in IQ, but the control group used were 
age-, gender- and race-matched controls from a normative database, whereas a sibling 
control  group  matched  for  socioeconomic  status  would  have  been  ideal
216,264.  A  meta-
analysis
114 of cognitive studies in SCA, including comparison between children without SCI 
and controls, showed a small effect size in IQ measures, with patients approximately 4-5 
points lower than controls. Results from the present study, using mainly siblings but also 
age-  and  race-matched  controls  concurrently  tested  with  patients,  did  not  provide  any 
evidence  to  suggest  marked  differences  in  IQ,  or  that  IQ  of  patients  was  outside  the 
average  range.  It  is  possible  that  the  2-subtest  WASI,  which  does  not  give  verbal  or 
performance IQ, may not be specific enough for more subtle discrepancies in cognition 
between patients and controls. Performance IQ, made up for perceptual organisation and 
processing speed, has been associated with cerebral blood flow
254 and basal ganglia and 
thalamus volume
331 and may also be associated with white matter integrity.        
Results  from  multiple  executive  functioning  tasks  are  also  reported,  also  showing  no 
differences  between  patients  and  controls  in  attention,  visual  processing  speed,  or 
cognitive flexibility. Executive functioning deficits are often reported in children with SCI 
compared to those without SCI
115,  but  none  have  yet  reported  executive  dysfunction  in 
those without SCI compared to healthy controls.   122 
No information about socioeconomic status was available for these subjects, although 10 of 
14 controls (71%) were siblings of patients, and all were of the same ethnic background. 
Although socioeconomic status and parental education are both relevant factors in a child’s 
cognitive profile
252, it is unlikely these factors are so different between patient and control 
groups to mediate a statistically significant effect in white matter microstructure. 
The observed differences in white matter microstructure seen in our patient group do not 
appear  to  be  related  to  any  specific  underlying  cognitive  deficits  detectable  by  the 
administered neuropsychological battery. However, changes in white matter microstructure 
may  be  indicative  of  future  cognitive  difficulties  in  general  measures  such  as  academic 
achievement, as one study reported 27% of children with SCA without SCI experienced 
poor academic achievement compared to only 6% of healthy siblings
227. With this sample, 
future  work  is  needed  to  investigate  academic  performance  and  cognitive  functioning 
longitudinally  and  to  elucidate  the  effects  of  chronic  oxygen  saturation  on  white  matter 
microstructure and general cognitive function.  
7.3.3  Implications for treatment 
Nocturnal oxygen desaturation in children with SCA has been reported to predict central 
nervous system events
94, and to be associated with poorer performance on the D-KEFS 
Tower test
162. The present study establishes a link between daytime oxygen saturation and 
white  matter  microstructural  abnormality,  which  may  be  potentially  ameliorated  with 
interventions to reduce hypoxic exposure, most practically overnight
279. Studies examining 
the effect of altitude exposure suggest that longer-term experience of hypoxia is associated 
with widespread decreases in FA
332, but the thresholds for chronic hypoxic exposure and 
whether these changes are reversible remains uncertain. These DTI metrics may serve as 
biomarkers  for  future  randomised  controlled  trials  in  SCA  to  investigate  white  matter 
microstructure  before  and  after  a  period  of  overnight  respiratory  support  or  other 
experimental  or  standard  treatments  such  as  chronic  blood  transfusion  or 
hydroxycarbamide.  
7.3.4  Conclusion 
In  a  cohort  of  children  and  adolescents  with  SCA  with  no  evidence  of  SCI,  markers  of 
physiological disease severity (i.e. daytime oxygen saturation) are significantly correlated 
with  white  matter  microstructure  in  anterior  inter-hemispheric  pathways.  These  results 
underline the importance of maintaining high levels of oxygen saturation in SCA to avoid 
damage to inter-hemispheric white matter and potentially set DTI metrics as a biomarker for 
monitoring potential therapeutic effects.     123 
Chapter 8.  General Discussion 
This  thesis  overviewed  SCD  in  respect  to  the  principal  medical  complications, 
epidemiology,  public  health  and  treatments,  as  well  as  the  neurological  and 
neuropsychological  sequelae  of  the  disease.  Ischaemic  events  secondary  to  chronic 
anaemia in childhood are discussed with neuroimaging and neurocognitive findings. The 
aim of this thesis was to incorporate new quantitative MRI analyses and neuropsychological 
testing results to bridge a gap in the existing literature,  and to  determine neuroimaging 
biomarkers of sickle cell disease severity. 
8.1  Main Findings 
First,  this  thesis  summarises  the  IQ  literature  in  SCD,  in  those  studies  that  used  MRI-
defined groups based on presence or absence of SCI. There is a commonly reported trend 
in  the  SCD  cognitive  literature  corresponding  to  a  step-wise  trend  with  lesion 
burden
199,216,217: those with evidence of SCI perform worse than those patients with normal 
MRI, and those with normal MRI perform worse than controls. The current findings from a 
sample of previously unreported patients showed SCD patients, regardless of abnormality 
seen  on  T2-weighted  MRI,  have  significantly  lowered  full-scale  IQ  than  appropriately 
matched controls. Patients with SCI had lower mean full-scale IQ than patients without, 
although  not  significantly  lower.  These  results  imply  cognitive  dysfunction  may  not  be 
exclusively a result of visible ischaemic injury (i.e.  SCI), but may be due to the chronic 
disease process. 
The following three chapters discuss quantitative neuroimaging biomarkers of the disease 
process,  including  volumetric  differences,  longitudinal  whole-brain  atrophy  and  diffusion 
characteristics.  
After  expanding  on  a  previously  published  report  (see  Appendix  B),  patients  in  a  larger 
cohort were found to have decreased volumes of specific, subcortical structures, in groups 
corresponding  to  lesion  burden,  mirroring  the  step-wise  trend  seen  in  the  cognitive 
literature. Similar to the results found in the full-scale IQ chapter, both patient groups, with 
and  without  SCI,  had  significantly  lower  mean  volumes  than  controls  for  the  bilateral 
cerebellar cortices, left amygdala and total subcortical grey matter volume. This chapter 
also showed significant negative correlations with age in patients without evidence of SCI 
comparable to controls, while no correlations were found in patients with evidence of SCI; 
this may indicate differential patterns of brain maturation from childhood to adulthood.   124 
From the SIT trial, a subset of those randomised to transfusion treatment or standard care 
had high-resolution T1-weighted data in which the percentage of brain volume change over 
three years of the trial could be assessed. There was evidence of atrophy in total brain 
volume over 3 years in all SCD patients, with rates of atrophy similar to those seen in older 
people with small vessel disease or traumatic brain injury. These findings also revealed no 
protective effect of transfusion treatment, in contrast to the main hypothesis.  
The  final  chapter  showed  marked  differences  in  diffusion  characteristics  between  those 
patients without evidence of SCI compared to controls. There was evidence of reduced 
fractional anisotropy, as well as increased diffusivity in widespread areas across the brain. 
Radial diffusivity, a marker of reduced myelination and membrane permeability (i.e. reduced 
white  matter  integrity)  correlated  significantly  with  haematological  markers  of  disease 
severity (i.e. oxygen saturation and haemoglobin). This result underlines the importance of 
maintaining high levels of oxygen saturation to avoid white matter damage, and sets these 
DTI metrics as a biomarker for monitoring potential therapeutic effects. 
These findings are consistent with the hypothesis of a global diffuse pattern of brain injury, 
related  to  the  effects  of  chronic  illness  (i.e.  chronic  anaemia  and  chronic  intermittent 
hypoxia). These four chapters extend the neuroimaging literature, further defining the extent 
of neurological injury in children with SCD.  
8.2  Future work 
SCD  has  been  called  a  developmental  disorder
296,  with  a  range  of  neurological 
complications resulting from chronic anaemia and oxygen desaturation from a very young 
age.  Clinical  neuroimaging  has  long  been  used  to  routinely  diagnose  cerebral  infarction 
during hospitalisation after a suspected event, or for screening in clinical trials, such as SIT. 
Only in the last 10 years has MRI been systematically applied in research settings. As MR 
systems, software and analysis techniques become more advanced, there is much promise 
for the future in SCD neuroimaging research. 
In SCD, the deep white matter in the centrum semiovale is vulnerable tissue where SCI 
frequently  occur.  DTI  results  from  Chapter  7  of  this  thesis  showed  marked  diffusion 
abnormalities  in  normal-appearing  white  matter,  compared  to  controls.  There  are  some 
limitations to DTI and tractography: multiple fibre orientations within the same voxel can 
skew  results  and  DTI  indices  can  lack  of  specificity
333.  Although  DTI  processing  in  this 
thesis used a model-dependent approach to fit two fibre orientations per voxel, there are 
more  advanced,  model-free  approaches  such  as  spherical  deconvolution
334,  which  can 
extract  directly  the  underlying  fibre  orientation,  and  neurite  orientation  dispersion  and   125 
density  imaging  (NODDI)
335,  which  can  measure  density  and  orientation  dispersion 
properties of axons in white matter and dendrites in grey matter. Spherical deconvolution 
may be able to give more reliable tractography results especially in areas of crossing fibres, 
while NODDI may be able to disentangle the factors that make up fractional anisotropy for 
more specific interpretation of pathology.  
Cerebral blood flow (CBF) studies have shown areas of decreased perfusion corresponding 
to areas of structural abnormality (i.e. stroke-like lesions)
93,336, while elevated values were 
found  in  patients  with  no  MRI  abnormality
259,260,337,338    Elevated  CBF  appears  to  be  a 
compensatory measure caused by vasodilation secondary to chronic anaemia
91. Whether 
areas  of  decreased  perfusion  can  predict  localised  ischaemic  events  remains  to  be 
determined.  Arterial  spin  labelling  perfusion  MRI  can  non-invasively  measure  CBF  in 
children with SCD
254,259–261,277. Dynamic ASL acquisitions are assocated with haemodynamic 
parameters, such as arrival time and dispersion of the bolus of labelled blood, which may 
give useful information about the underlying vasculature.   
Task-based and resting-state functional MRI (fMRI) tasks rely on a normal arterial input 
function, and detection of blood-oxygen level dependent (BOLD) activation in SCD patients 
may  be  compromised  due  to  anaemia  and  abnormal  haemodynamics
92,339,  even  if 
underlying neuronal activity was intact. A previous task-based fMRI study looking at visual 
stimuli showed BOLD effect activation was not strongly associated with resting CBF, but 
there was strong association with full-scale IQ
340. The authors suggest the inability to mount 
an appropriate haemodynamic response to support increased neural activity
341 underpins 
potential cognitive dysfunction in SCD. Further work is needed to first calculate a potential 
abnormal haemodynamic response function using task-based fMRI in treated and untreated 
children with SCD, then to use that information in resting-state fMRI, which can allow for 
analysis of connectivity networks underlying attention, mentalising, and thought processing.  
8.3  Post-doctoral research position 
The  quantitative  neuroimaging  experiments  discussed  in  this  thesis  provide  a  base  to 
explore  the  effect  of  chronic  oxygen  desaturation  on  the  brain.  In  2014,  funding  was 
secured from Great Ormond Street Hospital Children’s Charity for a post-doctoral research 
position to start in early 2015, in which there are two parallel studies to take place.    126 
8.3.1  POMS II 
First, the project includes neuroimaging analysis for a proof-of-concept clinical trial, funded 
by the National Institutes for Health Research/Research for Patient Benefit stream. The trial 
is  an  extension  of  POMS
163,  in  which  30  adult  patients  and  30  paediatric  patients  will 
receive either auto-adjusting continuous positive pressure therapy or oxygen therapy for six 
months. The choice of intervention is based on patient preference during a 30-day pilot that 
will  complete  in  December  2014.  The  main  trial  aim  is  that  the  intervention  will  reduce 
frequency and severity of pain symptoms, improve quality of life and cognition. There is 
some  evidence  in  adults  with  obstructive  sleep  apnoea  that  treatment  may  potentially 
reverse  acute  hypoxic  damage  to  the  brain
279.  All  patients  will  undergo  MRI  before 
randomisation and after trial exit, with advanced sequences on a 3T MRI scanner. Detailed 
neuropsychological  testing  will  be  performed  at  randomisation  to  the  trial,  and  tests 
sensitive to processing speed, visuomotor coordination, attention and concentration will be 
performed at trial exit. 
8.3.2  SAC follow-up 
Second, the project is to recruit up to 84 patients with SCD who have participated in Sleep 
Asthma Cohort (SAC) study
161, which investigated nocturnal hypoxaemia between 2005-
2014.  The  objectives  of  SAC  were  to  assess  asthma  risk  factors  associated  with  pain 
episodes  and  hospitalisations  and  to  define  the  relationship  between  sleep-disordered 
breathing and pulmonary complications. The aim of the follow-up project to begin in early 
2015 is to determine neuroimaging and neurocognitive biomarkers specifically for chronic 
oxygen saturation on the brain by applying advanced sequences on a 3T MRI scanner and 
detailed neuropsychological testing. A previous study in this cohort of children has linked 
poor  executive  function  performance  on  the  D-KEFS  Tower  task  with  nocturnal 
haemoglobin oxygen saturation
162. The main hypothesis of the study is that subtle brain 
insults due to chronic nocturnal hypoxia have a profound effect on structural abnormality of 
the brain as well as short-term and working memory, cognitive flexibility and processing 
speed. 
8.3.3  MSc projects 
In  2015,  two  students  doing  their  research  project  as  part  of  the  Applied  Paediatric 
Neuropsychology MSc will be linked to the SAC follow-up study.  
 
   127 
!  “White matter lesions and cognitive profiles in children and adults with SCD” 
The aim of this project is to establish a link between size and location of SCI, cognitive 
ability  and  school  performance.  Using  high-resolution  T2-weighted  MRI,  SCI  will  be 
identified  by  a  neuroradiologist  and  the  student  will  manually  trace  lesion  volume.  The 
hypothesis  is  that  children  and  adults  will  have  differing  neuropsychological  profiles 
correlated with the number of lesions, total lesion size and location of infarcted tissue. 
!  “Structural  and  neuropsychological  correlates  of  nocturnal  hypoxaemia  in 
children and adults with SCD” 
The aim of this project is to investigate brain structures that are susceptible to hypoxia, 
such as the hippocampus, as well as white matter pathways connecting the hippocampus 
with cortical regions. This project will apply high-resolution T1-weighted images to manually 
trace hippocampal volume and diffusion tensor imaging to virtually dissect medial temporal 
lobe  pathways,  along  with  neuropsychological  testing  aimed  at  memory  function.  The 
hypothesis is that hippocampal volumetric deficits and altered white matter pathways are 
related to poorer performance on learning and memory tasks.     128 
Appendix A: Selected Neuropsychological Tests 
 
Appendix Figure 1. The Trail-making test – visual scanning 
condition  (Scanning)  measures  visuomotor  processing 
speed  and  attention.  In  this  task,  the  subject  is  presented 
with this A3 landscape page with various circles of different 
numbers  and  letters,  and  asked  to  make  a  single  mark 
through all the circles with the number “3”, as fast as possible 
without making mistakes Completion time is recorded. 
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Appendix  Figure  2.  The  Trailmaking  test  –  number-letter 
switching  condition  (Switching)  requires  cognitive  flexibility, 
attentional-set  shifting  and  motor  speed.  In  this  task,  the 
subject  is  presented  with  this  A3  landscape  page  with 
various circles of different numbers and letters, and asked to 
draw lines to connect circles with letters and numbers, in the 
order of “1-A-2-B-3-C” etc. Completion time is recorded. 
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Appendix  Figure  3.  The  Colour-Word  Interference  – 
inhibition/switching  condition  (CWI),  a  version  of  the 
commonly  known  Stroop  test,  measures  naming  speed, 
reading speed, verbal inhibition and cognitive flexibility. The 
subject is given this page with names of colours written in 
the same ink colour to the words that are printed, and words 
written in dissonant ink colours to the words that are printed. 
In  this  condition,  the  subject  is  asked  to  switch  back  and 
forth between naming the dissonant ink colours and reading 
the words that are in the black boxes. Completion time is 
recorded.    131 
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Appendix Figure 4. The Behaviour Rating Inventory of Executive Functions (BRIEF) is a parent 
questionnaire for children younger than 18, consisting of 86 items in eight non-overlapping 
behavioural regulation and metacognition clinical scales. The Global Executive Composite score 
takes into account all the clinical scales and represents the child’s overall executive function. 
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Appendix C: Presentations attributed to this thesis  
Oral Presentations 
Kawadler  JM,  Kirkham  FJ,  Barker  S  &  Clark  CA.  White  matter  abnormalities  in 
asymptomatic children with sickle cell anaemia. 19th Annual meeting of the British Chapter 
of ISMRM. York, UK, 24-25 September 2013. 
Kawadler  JM,  Kirkham  FJ,  Barker  S  &  Clark  CA.  White  matter  abnormalities  in 
asymptomatic children with sickle cell anaemia. Sickle Cell in Focus - 7th Annual Meeting. 
London, UK. 6-8 June 2013. 
Kawadler JM, Clayden JD, Kirkham FJ, Cox TC, Saunders DE, Clark CA. Subcortical and 
Cerebellar  Volumetric  Deficits  in  Pediatric  Sickle  Cell  Anemia.  International  Society  for 
Magnetic Resonance in Medicine - 21st Annual Meeting. Salt Lake City, USA, 20-26 April 
2013. 
Kawadler JM, Clayden JD, Kirkham FJ, Cox TC, Saunders DE, Clark CA. Subcortical and 
Cerebellar  Volumetric  Deficits  in  Paediatric  Sickle  Cell  Anaemia.  British  Society  of 
Haematology - 53rd Annual Meeting. Liverpool, UK, 15-17 April 2013.  
Kawadler  JM,  Clayden  JD,  Kirkham  FJ,  Cox  TC,  Saunders  DE,  Clark  CA.  Subcortical 
volumetric differences in children with sickle cell disease. 18th Annual Meeting of the British 
Chapter of ISMRM. Cambridge, UK, 11-13 September 2012. 
Poster Presentations 
Kawadler  JM,  Kirkham  FJ,  Barker  S,  Cox  TC,  Clark,  CA.  White  matter  abnormalities  in 
children  with  sickle  cell  anemia:  Potential  link  with  oxygen  desaturation.  International 
Society for Magnetic Resonance in Medicine – 22nd Annual Meeting. Milan, Italy, 10-16 
May 2014. 
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